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Summary 
 
Ras is a monomeric membrane-associated GTP-binding protein that fluctuates between two 
distinct conformational states defined as active (GTP-loaded) or inactive (GDP-loaded). Ras 
protein is widely considered a critical pro-mitogenic signalling molecule with an essential role 
in cell cycle progression. This notion is based on multiple studies documenting that interfering 
with Ras activation in cells emerging from quiescence in response to growth factor stimulation 
prevents cell cycle entry and/or progression. This cell cycle blockade correlates with a drop in 
CyclinD levels (one of the key drivers of G1-to-S transition). Furthermore, Ras activation not 
only during G1 but also specifically during G2 phase in continuously cycling cells has been 
reported. Thus, it is assumed that Ras is engaged to function at multiple preordained stages 
through the cell cycle, arguably for phase-transition as well as cell fate decision-making. 
However, the precise role and importance of Ras-dependent signalling at each of those stages 
could not be proven to date, owing to the lack of experimental approaches for the acute 
inhibition of Ras activity. 
We have developed a novel biochemical tool that enables direct, acute interference with Ras 
activity at any desired time-point of the cell cycle. The system consists of two protein 
partners: an anchor unit (FKBP-mCherry-K-Ras-hvr) confined to the cellular membrane and an 
effector unit coupled to the catalytic domain of the Ras-GAP NF1. The latter is recruited to 
the plasma membrane upon addition of the small molecule heterodimerizer, rendering it 
close to membrane-bound Ras. Biochemical analysis proved that EGF-dependent activation 
of Ras and its downstream effector Erk was fully abrogated by short-term (15 min) pre-
treatment with the heterodimerizer. By examining the activity of other small GTPase family 
member like Rap1, largely unaffected in presence of the heterodimerizer, we provide 
evidence that the heterodimerization system is rather accurate and selective in inhibiting Ras 
alone. This statement is also supported by the analysis performed in wild type cells and those 
transduced with one of the components of the heterodimerization system. Using this 
approach to interrogate the time periods and effectors engaged by Ras throughout G1 
confirmed a critical role for Ras in cell cycle entry of growth factor-stimulated quiescent cells 
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and G1/S transition through the regulation of cyclinD1 expression. Thus, in T98G cells 
emerging from quiescence, progressive ablation of Ras function throughout G1 phase 
revealed a necessity for mitogenic Ras signalling deep into G1, up to 5 hours after growth 
factor stimulation. In parallel, flow cytometric cell cycle profiling of asynchronous, actively 
cycling cells showed a G0-G1 arrest in the lack of Ras activity. Further analysis in continuously 
proliferating T98G cells indicated that the absence of Ras function in G2 and early G1 phase 
led to a decrease in the ensuing S phase entry accompanied by a reduction of cyclinD1 
expression. Dissection of signalling downstream of Ras identified Erk and excluded PI3K/Akt 
and Ral as the mediator of its signals to the cell cycle machinery.  
In conclusion, we have charted the temporal signalling program of Ras during G0/G1/S phase 
progression employing a novel experimental methodology for the acute and specific 
inhibition of Ras that may have broad applicability in many areas of signal transduction and 
molecular oncology research. 
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Zusammenfassung  
 
Ras ist ein, als Monomer vorliegendes, Membran-assoziiertes GTP-Bindeprotein, welches 
zwei verschiedene Konfirmationen annehmen kann, welche als aktive (GTP-gebunden) und 
inaktive (GDP-gebunden) Form definiert sind. Das Ras-Protein wird als entscheidendes pro-
mitotisches Signalmolekül, mit einer essentiellen Rolle im Zell-Zyklus-Fortschritt, angesehen. 
So wurde in zahlreichen Studien gezeigt, dass eine Störung der Ras-Aktivierung in Zellen, 
welche durch die Stimulation mit Wachstumsfaktoren aus dem Ruhestadium erweckt 
wurden, den Eintritt bzw. das Voranschreiten des Zellzyklus verhindert. Diese Blockade des 
Zellzyklus geht einher mit einem Abfall des Cyclin-D-Spiegels (ein Schlüssel-Faktor im 
Übergang von G1 zu S). Des Weiteren wurde eine Ras-Aktivität nicht nur während der G1-
Phase, sondern speziell auch während der G2-Phase nachgewiesen, wenn die Zellen 
kontinuierlich den Zellzyklus durchlaufen. Daher wird vermutet, dass Ras in vielen Phasen des 
Zellzyklus eine wichtige Rolle spielt, besonders beim Übergang der einzelnen Phasen, sowie 
bei der Entscheidung über das Schicksal der Zelle. Die genaue Rolle und Bedeutung des Ras-
abhängigen Signalweges während der einzelnen Phasen konnte bis heute jedoch noch nicht 
beschrieben werden, da experimentelle Wege, die Ras Aktivität unmittelbar zu inhibieren, 
fehlen. 
Wir haben ein neues biochemisches Werkzeug entwickelt, welche es uns ermöglicht die Ras-
Aktivität direkt und unmittelbar zu jedem gewünschten Zeitpunkt des Zellzyklus zu stören. 
Das System besteht aus zwei Protein-Partnern, einer Anker-Einheit (FKBP-mCherry-K—Ras-
hvr), welche an die Zellmembran gebunden ist und einer Effektor-Einheit, welche mit der 
katalytischen Domäne von Ras-GAP NF1 verbunden ist. Letztere wird nach Zufügen des 
niedermolekularen Heterodimerisierer an die Plasmamembran rekrutiert, in die Nähe des 
Membran-gebundenen Ras. Biochemische Analysen haben gezeigt, dass kurzzeitige 
Vorbehandlungen (15 min) mit dem Heterodimerisierer die EGF-abhängige Aktivierung von 
Ras und dessen nachfolgendem Effektor Erk vollständig aufheben können. Durch die 
Untersuchung anderer Mitglieder der Familie der kleinen GTPasen, wie Rap1, welches von 
der Anwesenheit des Heterodimerisierers weitestgehend unaffektiert blieb, konnten wir 
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zeigen, dass das Heterodimerisierer-System recht präzise und selektiv ausschließlich Ras 
inhibiert. Diese Beobachtung wird durch Analysen in wild typ Zellen und Zellen, die nur mit 
einem Bestandteil des Heterodimerisierer-Systems transduziert wurden, unterstützt. Mit 
Hilfe dieser Vorgehensweise konnten die Ras-anhängigen Zeiträume und Effektoren während 
der G1 Phase untersucht werden. Dabei zeigte sich, dass Ras eine wichtige Rolle einnimmt, 
wenn Zellen aus dem Ruhezustand nach Wachstumsfaktor-Stimulation in den Zellzyklus 
eintreten, sowie beim Übergang der G1-Phase zur S-Phase, durch die Regulierung der 
CyclinD1-Expression. Durch die schrittweise Blockade der Ras-Funktion zu unterschiedlichen 
Zeitpunkten während der G1 Phase in T98G Zellen, welche aus dem Ruhezustand kommen, 
konnte die Notwendigkeit für die mitogene Ras-Signaltransduktion, für bis zu 5 Stunden nach 
der Stimulation mit Wachstums-Faktoren, nachgewiesen werden. Zusätzlich zeigte die 
Zellzyklus-Analyse asynchroner, aktiv zirkulierender Zellen mittels Durchflusszytometrie 
einen G0-G1-Arrest, wenn Ras nicht aktiv ist. Weitere Analysen in kontinuierlich teilenden 
T98G Zellen weist darauf hin, dass eine fehlende Ras-Funktion in der G2- und der frühen G1-
Phase zu einem verminderten Eintritt in die S-Phase führt, begleitet von einem Rückgang der 
CyclinD1-Expression. Untersuchungen der Signalübertragung nachfolgend auf Ras zeigten, 
dass Erk und nicht PI3K/Akt der Mediator der Signaltransduktion durch Ras in der Zellzyklus-
Maschinerie ist.  
Zusammenfassend konnten wir, mit Hilfe einer neuen experimentellen Methode für die 
sofortige und spezifische Inhibition von Ras, einen zeitlichen Verlauf des Ras-Signalweg 
während des Voranschreitens der G0-, G1- und S-Phase skizzieren, welcher eine breite 
Anwendbarkeit in verschiedensten Bereichen der Signaltransduktion und molekularen 
onkologischen Forschung haben kann. 
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1. Introduction 
1.1. Small G-proteins  
G proteins, guanine nucleotide binding proteins, form a large superfamily and are involved in 
many signal transduction cascades. According to the molecular structure they can be divided 
into two big families: the heterotrimeric and monomeric G proteins.  
The heterotrimeric G proteins are composed of three different subunits: alpha, beta and 
gamma. They transmit signals from the plasma membrane receptors to intracellular proteins 
affecting several signalling pathways, vesical trafficking and protein synthesis.  
The monomeric G proteins are characterized by a low molecular weight that vary between 20 
and 30 kDa. Because to their size they are usually referred to as small GPT-binding proteins. 
They are further classified into five subfamilies: Ras, Rho, Rab, Arf and Ran (Bourne, Sanders 
et al. 1990). Despite the structural similarities, each subfamily has a specific intracellular 
function. Ras proteins (collectively referring to N-, H- and K-Ras) are mainly involved in cell 
proliferation and gene expression. The Rho proteins control cytoskeletal reorganization as 
well as gene expression. Rab together with Arf proteins cooperate to regulate the traffic of 
vesicles while the Ran subfamily is necessary in nucleocytoplasmic transport and microtubule 
organisation during cell cycle progression (Matozaki, Nakanishi et al. 2000).  
Small G proteins have a conserved amino acid sequence and therefore show a 30-55% 
homology (Hall 1990, Valencia, Chardin et al. 1991). These conserved regions are localized in 
the GDP/GTP-binding site (so-called G-domain) of the protein. All members of this family have 
a specific region responsible for the interaction with their downstream effectors. Small G 
proteins, but not all, undergo post-translational modifications in their COOH- or NH2-termini 
(Moss and Vaughan 1995). Their intracellular localization is dependent on these post-
translational modifications that determine if proteins will be present at the plasma 
membrane or other membrane compartments. Most of the GTP-binding proteins are found 
at the cytosolic side of the different membranes, whereas Ran is the only one that can be 
localized in the cytosol or in the nucleus (Takai, Sasaki et al. 2001).  
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1.2. Ras protein, a molecular switch  
Ras proteins have an intrinsic ability to continuously fluctuate between two distinct 
conformational states depending on whether they are bound to GDP or GTP (Guanosine 
diphosphate and Guanosine-5'-triphosphate, respectively). Ras is activated upon GTP binding 
(active state) and can interact with its downstream effectors until hydrolysis of GTP to GDP 
occurs, leading to an inactive GDP-bound Ras (Fig.1A). Both GDP and GTP bind to the effector 
lobe (G domain) that is composed of five highly conserved loops. Binding of GTP is ensured 
by the interaction between three loops G1, G4 and G5, that induce the conformational change 
in the remaining loops G2 and G3, known as Switch I and II regions (Fig.1B). This new 
orientation of the protein facilitates the GTPase process by exposing the catalytic Mg2+ and 
reactive water molecules (Vetter and Wittinghofer 2001, Wittinghofer 2006, Bos, Rehmann 
et al. 2007). 
All GTP-binding proteins have the same basic structure composed of six β-sheets and five α-
helixes. However, the nucleotide-binding site exposes a sequence of 4 or 5 amino acids that 
are highly conserved. There are two essential motifs that mediate the nucleotide binding, the 
N/TKXXD motif and the GXXXXGKS/T motif (Saraste, Sibbald et al. 1990). The latter includes 
the conserved phosphate-binding loop (P loop). Moreover, an Asp side chain in the DXXG 
motif and Ala146 of the SAK motif ensures the high specificity for guanine nucleotides. 
 
Figure 1. Ras, a small GTPase protein. 
A) Simplified scheme of Ras cycling between the GTP- and GDP-bound forms. B) General structure of a guanine 
nucleotide binding protein. Image is taken from (Vetter and Wittinghofer 2001). 
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Once GTP is bound, the γ-phosphate oxygen creates 2 hydrogen bonds with two specific 
residues localised at the 35th position in Switch I and at the 60th position in Switch II, Threonine 
and Glycine respectively. The latter also binds Mg2+ ions by its side chain. Hydrolysis of the 
phosphate group induces relaxation of the Switch regions (Vetter and Wittinghofer 2001). 
 
1.3. Ras, a monomeric G protein 
Ras is the best characterized protein among the small G proteins. Its discovery dates back to 
the 1960s when viral genes with the capacity to transform cells in culture were identified. The 
nomenclature ‘RAS’ stems from the ability of these genes to induce sarcomas in rats, and its 
isoforms denominated by prefixes based on the discoverers’ name, as H-Ras and K-Ras for 
Harvey and Kirsten murine sarcoma viruses, respectively (Der, Krontiris et al. 1982, Parada, 
Tabin et al. 1982, Santos, Tronick et al. 1982). More than 20 years later, other research groups 
observed the ability of these RAS genes to transform mouse fibroblasts (NIH3T3). Further 
studies identified a single missense mutation in codon 12 as the mechanism that conferred 
oncogenic potential to H-RAS and K-RAS genes. The occurrence of this point mutation at a 
high frequency in lung and colon cancer cells was soon documented (Reddy, Reynolds et al. 
1982, Tabin, Bradley et al. 1982, Taparowsky, Suard et al. 1982, Capon, Seeburg et al. 1983). 
The third human RAS gene was first discovered in neuroblastoma lines after which it was 
appropriately named N-Ras (Hall, Marshall et al. 1983, Shimizu, Goldfarb et al. 1983). The 
discovery of oncogenic Ras spun-off a completely new research area towards the 
understanding of cancer at the molecular level. Further use of the NIH3T3 cells and DNA 
sequencing method led to the discovery of human Ras genes in pancreatic cancers in addition 
to the lung and colon cancers (Cox and Der 2010). 
 
1.4. Ras isoforms 
There are four different Ras proteins encoded from only three human RAS genes that have 
similar biochemical properties, structure and 82-90% sequence identity. The four isoforms 
are N-Ras, H-Ras and two alternative RNA splice variants of K-Ras resulting in two distinct 
proteins: K-Ras4A and K-Ras4B.  
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The human RAS gene product is a 188-189 amino acid protein consisting of three functionally 
significant regions: the effector lobe, the allosteric lobe and the hypervariable region. The 
effector lobe, the first 86 amino acids of the N-terminus, is the most conserved region of the 
protein showing a 100% sequence identity between all four proteins (Buhrman, O'Connor et 
al. 2011). This identity emphasized the importance of the region as it comprises the site where 
the exchange between GDP and GTP takes place, also called G domain. In addition, part of 
the G domain are the two switch regions, Switch I and Switch II. Their physical conformation 
depends on whether GTP or GDP is bound to Ras. The protein sequence continues with the 
allosteric lobe (87-166 residues) (Hobbs, Der et al. 2016). Ras isoforms share a 78-82% 
sequence homology in this region that is thought to be important for the membrane 
orientation of Switch II (Parker and Mattos 2015). C-terminal hypervariable region, as 
suggested by the name, is the least conserved between the isoforms with only 4% similarity. 
Together with the allosteric lobe they mediate proper localization and orientation of Ras on 
the plasma membrane, especially of the G domain for specific downstream effectors 
(Abankwa, Gorfe et al. 2008, Abankwa, Gorfe et al. 2010).  
 
1.5. Post-translational modifications 
It is well accepted that Ras can be biologically active only after being anchored to the plasma 
membrane. Over the last decades, many studies described a general mechanism on how 
newly synthesized Ras proteins undergo a number of post-translational modifications to 
ensure their translocation and association to the plasma membrane (Fig. 2). Main target for 
Ras post-translational processing are the C-terminal 24-25 residues that include the 
hypervariable region and the CAAX-box, emphasizing the major differences between Ras 
isoforms. Each of them is target for a specific modification. The CAAX box is a tetrapeptide 
motif that consists of one cysteine residue (C), two aliphatic amino acids (A) and a last 
nonspecific amino acid (Ahearn, Haigis et al. 2011, Hobbs, Der et al. 2016). 
Like many other proteins Ras is synthesized in the cytoplasm. The first modification involves 
the covalent addition of a 15-carbon farnesyl isoprenoid lipid on the cysteine residue of the 
CAAX box catalysed by farnesyltransferase (FTase) (Casey, Solski et al. 1989, Hancock, Magee 
et al. 1989, Schafer, Kim et al. 1989). All Ras isoforms can undergo this type of modification, 
but in absence or inhibition of the FTase activity Ras is retained in the cytosol and therefore 
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not active. As a fail-safe mechanism, K- and N-Ras can be geranylgeranylated which allows 
further post-translational processing of the protein (Downward 2003). As a result an 
alternative C20 geranylgeranyl lipid is added to the protein. A proteolytic cleavage of the AAX 
peptide sequence followed by a carboxymethylation of the already farnesylated cysteine 
residue completes the modifications of the CAAX box. The last alterations occur in the 
endoplasmic reticulum (ER) and increase the hydrophobic nature of the C-terminus 
facilitating Ras association to the plasma membrane (Hancock, Cadwallader et al. 1991).  
Moreover, a second membrane targeting element is required and is in fact provided by 
specific sequences in the hypervariable region (hvr). Except for K-Ras4B, Ras proteins are 
covalently modified at their hvr cysteine residues by Golgi-associated palmitoyltransferases. 
These enzymes catalyse the addition of a single palmitic acid in case of N-RAS and two 
separate palmitoylation modification for H-Ras (Hancock, Paterson et al. 1990).  Proteins are 
further transported through the Golgi apparatus to the plasma membrane.  K-Ras4B instead 
has a polylysine sequence (175-180 residues) in its hvr with a positive charge that facilitates 
the interaction with the negatively charged groups on the cytosolic side of the plasma 
membrane. Due to this property K-Ras4B can escape the trafficking through Golgi; the exact 
mechanism is however not clear (Cox and Der 2010).  
Several studies revealed a connection between the specific modifications on Ras isoforms and 
their membrane localisation like in the case of H- and N-Ras where their different 
palmitoylation levels determine N-Ras localisation to the cis-Golgi and H-Ras distribution 
throughout the Golgi membranes (Lynch, Snitkin et al. 2015). Moreover, different lipid 
domain organisations were found for these two isoforms when they are bound to GDP or GTP. 
These lipid domains were organised in rafts only when H-Ras was bound to GDP and N-Ras to 
GTP (Rotblat, Prior et al. 2004, Eisenberg, Beckett et al. 2011).  
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Figure 2. Post-translational modifications of Ras proteins. 
Processing of Ras starts in the cytosol by farnesylation. It then translocates to the ER where it undergoes 
proteolysis and methylation. By means of an unknown mechanism, K-Ras traffics to the plasma membrane, 
whereas N/H-Ras palmitoylate in the Golgi apparatus and by means of transport vesicles attach themselves to 
the plasma membrane. After depalmitoylation N/H-Ras reenter the Golgi apparatus to palmitoylate again. RAS: 
H/K/N-Ras 
 
There are many other modifications on the hvr of Ras proteins not related with their 
translocation to the plasma membrane, but mainly affect the biological activity and 
interaction with downstream effectors. For example, K-Ras4B is the only isoform that has a 
Serine phosphorylation site at position 181 responsible for its translocation to 
endomembrane compartments. Phosphorylation sites found in H-Ras at position Y137 and N-
Ras at position Y32 altered the affinity of the Ras-binding domain of Raf protein (Ting, Johnson 
et al. 2015, Bunda, Heir et al. 2014, Downward 2003, Cox and Der 2010, Hobbs, Der et al. 
2016). 
Ubiquitylation of Ras isoforms, as another form of post-translational modification, was found 
to have different effects on Ras activity in a cell type dependant manner. In 2006 Jura et al. 
showed that ubiquitylation of H-Ras induced its internalization (Jura, Scotto-Lavino et al. 
2006), while few years later Baker et al. demonstrated that ubiquitylation at K117 position 
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enhanced its activation (Baker, Lewis et al. 2013). Monoubiquitylation of K-Ras at K147 was 
first though to accelerate GTP binding on Ras and consequently its interaction with 
downstream effectors. In 2015 it was shown that the real reason behind this Ras 
hyperactivation was an altered and weakened response to GTPase-activating proteins.  
As a final form of modification, K-Ras4B was found to be acetylated at position K104. Yang et 
al., identified an impaired conformation of Switch II region leading to a reduced activation of 
the protein (Yang, Nickerson et al. 2012).  
 
1.6. Guanine nucleotide exchange factors and GTPase activating proteins  
As mentioned earlier, Ras proteins have an intrinsic ability to cycle between the GDP and GTP-
bound states. The speed of this reaction was estimated to be about 30min, a rather slow 
turnover rate taking into account the kinetics of endogenous Ras activation (seconds to 
minutes) (Feuerstein, Goody et al. 1987, Trahey, Milley et al. 1987, Neal, Eccleston et al. 1988, 
John, Schlichting et al. 1989). This process of spontaneous GTP hydrolysis is accelerated by 
two groups of enzymes:  guanine nucleotide exchange factors (GEFs) and GTPase-activating 
proteins (GAPs) that lead to the activation or inactivation of Ras protein respectively 
(Wittinghofer and Waldmann 2000). The interaction between Ras protein and GEFs/GAPs 
initiates with the translocation of the latter from the cytosol to the plasma membrane where 
the G protein is localised. The plasma membrane recruitment of Son of Sevenless (SOS), one 
of the best characterised RasGEF, is mediated by Grb2 (adaptor growth factor receptor-bound 
2) with which SOS is constitutively bound. The SH2 domain of Grb2 brings the complex to the 
activated receptor tyrosine kinase. On the other hand, the plextrin homology (PH) and histone 
homology domains of SOS support the translocation due to their affinity for negatively 
charged phospholipids. 
Similarly, the SH2 domain of the first identified RasGAP (p120GAP) is responsible for its 
recruitment to the plasma membrane by binding to the phospho-tyrosine on the receptor 
tyrosine kinase and placing p120GAP in close proximity with RasGTP. This mechanism does 
not apply to all RasGAPs. Membrane localization of neurofibromin 1 (NF1), another RasGAP, 
is achieved after its binding with Spred1. This interaction involves the non-catalytic portion of 
GAP-related domain of NF1 and the N-terminal Ena/VASP Homology 1 (EVH1) domain of 
Spred1 (Dunzendorfer-Matt, Mercado et al. 2016). 
  Introduction 
 
8 
 
Given that Ras protein shows no preference or higher affinity for GTP or GDP and also the 
intracellular GDP:GTP ratios ranging between 1:10 to 1:50, nucleotide exchange would occur 
in favour of GEF-mediated accumulation of active Ras-GTP (Trahey and McCormick 1987, Bos, 
Rehmann et al. 2007). This reaction is reversed by the intrinsic GTPase activity of Ras and 
accelerated by GAPs. It is noteworthy that all GEFs and GAPs share a considerably large region 
of the interaction site with Ras, leading to the observation that Ras interaction with more 
than one GEF and/or GAP cannot happen simultaneously (Antonny, Chardin et al. 1991, 
Gideon, John et al. 1992, Allin, Ahmadian et al. 2001, Hennig, Markwart et al. 2015).  
A common feature of these two protein classes is their multi-domain structure and the high 
specificity to each G protein family, for instance Ras-GEFs have a CDC25 homology domain 
(CDC25-HD) combined with a Ras exchange motif (Uddin, Hussain et al. 2005), while Rho-GEFs 
contain a DH-PH tandem domain. In some cases few domains are shared between the GEFs 
and GAPs of different families, presumably to facilitate the crosstalk between various 
signalling pathways (Bos, Rehmann et al. 2007).  
 
1.6.1. General mechanism of GEFs 
Guanine nucleotide exchange factors (or GEFs) catalyse the GTP-loading of small GTP-binding 
proteins such as Ras. Several groups studied the interaction between G proteins and their 
corresponding GEF along with a nucleotide in binary complexes (RanGEF RCC1 and Ran) and 
demonstrated that G proteins have a high affinity for both. On the other hand, the interaction 
GEFs/nucleotide-bound G protein and nucleotide/GEF-bound G protein is weak. Thus, the G 
protein interaction with either one of them weakens the affinity for the other. Structural 
studies showed that GEFs function is to facilitate the nucleotide exchange by interfering with 
the P loop. To summarize, the nucleotide is strongly bound between the two Switch regions 
that interact with the P loop, phosphate group and Mg2+ ion. Once GEFs bind to the G protein, 
the Switch regions and the P loop undergo a conformational change occluding the 
magnesium-binding site. All the structural changes act as an inhibitor for phosphate binding 
and subsequently enhancing the nucleotide release (Vetter and Wittinghofer 2001, Bos, 
Rehmann et al. 2007). An additional player in this reaction is a glutamine residue in the Switch 
II region directed toward the phosphate groups, which enhances the release of the 
nucleotide. 
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1.6.2 General mechanism of GAPs 
 
GTPase-activating proteins (or GAPs) expedite GTP-hydrolysis of G-proteins by enhancing 
their enzymatic activity. The investigation of Ras interaction with a non-hydrolysable GTP 
analogue yielded initial hints in understanding the mechanism of action of GTPase-activating 
proteins. NF1 and p120GAP are the first and best characterised RasGAPs. Structural studies 
demonstrated that GAP’s arginine residues play an important role in the activation of Ras 
GTPase. More specifically Arg 1276 in NF1 and Arg 789 in p120GAP, termed arginine-fingers, 
attracted most of the attention as they were identified as the major contributors for the GAP-
mediated catalysis and were highly conserved among GAPs (Ahmadian, Stege et al. 1997). 
Further investigations demonstrated that the orientation of the water molecule in front of 
the γ-phosphate group is coordinated by the interaction between RasGAP and the 
Glutamine61 of Ras. Subsequently the water molecules are polarised and occluded from the 
active site. This transition state is further stabilized by the arginine-finger of the RasGAP 
already situated in the phosphate-binding site where it also neutralises its negative charge.  
The structure of GAPs is not well conserved leading to differences on how they approach and 
support GTPase activity of G proteins. However the general mechanism remains the same 
emphasizing the fact that GAPs function is mainly in supporting and stabilizing the transition 
state by supplying the catalytic arginine (Vetter and Wittinghofer 2001, Bos, Rehmann et al. 
2007).  
 
1.7. Ras signalling pathways 
Ras plays an important role in transmitting signals from the extracellular environment inside 
the cells and activating several pathways that result in cell growth, proliferation, survival, 
differentiation, migration and apoptosis (Fig.3). By virtue of its position at the plasma 
membrane it is amenable to activation by epidermal growth factor receptors (EGFR), T cell 
receptors or G protein coupled receptors. One of the best characterized signalling pathways 
most affected by Ras activity is the mitogen-activated protein kinase cascade (MAPK). The 
activation of this pathway starts when a ligand binds to the respective receptor tyrosine 
kinase, for example EGF (epidermal growth factor) binding on EGFR (Merchant, Voskresensky 
et al. 2008). EGF binding induces dimerization and phosphorylation of the receptor that in 
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turn interacts and binds to the SH2 domain of the adaptor protein Grb2 (Reuter, Morgan et 
al. 2000). The latter is associated with the RasGEF SOS through its SH3 (Src homology 3) 
domain, after being recruited to the plasma membrane. Ras, by default localized to the 
plasma membrane and in proximity with SOS, is then activated by exchanging GDP with GTP 
(Zenonos and Kyprianou 2013). Active Ras has the ability to recruit and bind Raf protein. As 
for Ras, Raf localization in proximity to the plasma membrane is essential for its proper 
function. The interaction between Ras and Raf leads to the release of 14-3-3 protein that is 
normally bound and therefore inhibits Raf. Once active, Raf forms heterodimers that induce 
translocation of the KSR1 (kinase suppressor of Ras) enzyme to the plasma membrane 
(Nandan and Yang 2011). KSR is a scaffold protein that is stably bound to MEK and its 
translocation brings MEK close to its activator – Raf (Morrison 2001). Consequently, MEK is 
phosphorylated and is able to further activate Erk. Phosphorylated Erk can act in the cytosol 
as well as in the nucleus. Most of the research has been focused on understanding how Erk 
can regulate transcription factors. Once inside the nucleus, Erk can regulate the expression of 
FOS transcription factor and phosphorylate c-Jun. Both of them bind to the AP1 transcription 
factor that leads to the expression of genes involved in proliferation like CyclinD1 (Downward 
2003).  
PI3K pathway can also be stimulated by active Ras. Normally, PI3Ks are composed of a 
regulatory and catalytic subunit, generally referred to as p85 and p110 respectively, which 
are activated by receptor tyrosine kinase by directly binding a phosphorylated residue on the 
receptor or an adaptor (Katso, Okkenhaug et al. 2001, Engelman, Luo et al. 2006, Yuan and 
Cantley 2008). This interaction is mediated by p85, whereas p110 converts 
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate 
(PIP3) (Carpenter, Auger et al. 1993, Zhao and Vogt 2008). Several studies have shown that 
active Ras is able to directly bind catalytic subunit p110, activating in this way the whole 
pathway (Shaw and Cantley 2006). Production of PIP3 induces the recruitment of two 
serine/threonine kinases, PDK1 and Akt. Phosphorylation of Akt at position Threonine308 by 
PDK1 (Alessi, James et al. 1997, Currie, Walker et al. 1999, Majumder and Sellers 2005) 
promotes survival through the following mechanisms: 1. inhibiting pro-apoptotic Bcl-2 family 
members (Cantley 2002, Engelman, Luo et al. 2006); 2. enhancing transcription of anti-
apoptotic and pro-survival genes by preventing the negative regulation of NF-kB; 3. inhibiting 
p53-mediate apoptosis by Mdm2 phosphorylation (Duronio 2008); 4. blocking FOXO 
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(forkhead box transcription factor) activity responsible for the transcription of proteins that 
promote cell death; and 5. phosphorylation of TSC2 (tuberous sclerosis complex 2) that leads 
to the subsequent activation of Rheb-GTP and mTORC1 complex (mammalian target of 
rapamycin complex 1) to increase protein synthesis (Engelman, Luo et al. 2006). In parallel, 
mTORC2 (mammalian target of rapamycin complex 2) sustains Akt activity by further 
phosphorylating the protein at position Serine 473 (Hresko and Mueckler 2005, Sarbassov, 
Guertin et al. 2005, Sarbassov, Ali et al. 2006). A negative feedback is initiated from one of 
the targets of mTORC1, S6 kinase, to terminate the PI3K signalling at the level of the adaptor 
protein on the cytoplasmic part of the RTKs (Harrington, Findlay et al. 2004, O'Reilly, Rojo et 
al. 2006, Carracedo and Pandolfi 2008, Courtney, Corcoran et al. 2010).  
Figure 3. Scheme of Ras signalling pathways. 
EGFR activation by its ligand leads to GTP loading of Ras mediated by Grb2/SOS proteins. The 2 most important 
downstream pathways, MAPkinase and PI3K-AKT are activated by GTP-bound Ras and induce or inhibit gene 
transcription. Other Ras mediated pathways are the Ral and PLCɛ cascades. For further details refer to section 
1.7. 
 
A third signalling network altered by Ras activity is the RalGEF-Ral effector pathway (Albright, 
Giddings et al. 1993). In this case, in contrast to the previously described crosstalks, the 
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downstream effector of Ras is a member of the GEF family, RalGDS (Ral guanine nucleotide 
dissociation stimulator). Ral is another small GTP-binding protein that transitions between 
GTP-bound active and GDP-bound inactive state. Identification of RalGDS as an effector of Ras 
was confirmed by the introduction into the cell (COS7) of a mutant Ras (RasV12G37) that 
stimulated RalGEF activity (Urano, Emkey et al. 1996, Murai, Ikeda et al. 1997, Bos 1997). 
Moreover, RasV12G37 displayed a high selectivity for RalGEF and did not interact with neither 
Raf nor PI3K. Even though the two Ral proteins, A and B, share a 100% sequence identity in 
the effector binding site, they have different functions within the cell especially due to their 
distinct localisation. RalA is mostly found localized close to the plasma membrane and 
endosomes, while RalB is primarily associated with endosomes (Shipitsin and Feig 2004). 
Nonetheless, depending on its activation state or phosphorylation Ral localization can vary 
(Cascone, Selimoglu et al. 2008, Lim, Brady et al. 2010). The best characterized Ral function is 
its involvement in regulating exocytosis. Further studies showed a direct activation of 
phospholipase C delta 1 and D1 (Luo, Liu et al. 1997, Sidhu, Clough et al. 2005). The latter 
increases production of lipid secondary messengers. Another effector of RalA, even though 
less characterized, is filamin involved in actin reorganization. Expression of several genes is 
regulated by this signalling pathway and mediated by myriad transcription factors like c-Jun 
activation, FOXO4, STAT3, c-Fos and NF-kB (Neel, Martin et al. 2011).  
Phosphoinositol-specific phospholipase C (PLC) is a signalling enzyme that induces production 
of PIP3 which in turn increases intracellular Ca2+ and DAG (diacylglycerol). The latter is able to 
activate several isoforms of protein kinase C (PKC). Up to date, four different classes of PLC 
are identified: β, γ, δ and ɛ. Kelley et al.  demonstrated that PLCɛ was directly regulated by 
Ras through its C-terminal Ras-binding domain in a GTP-dependent manner (Kelley, Reks et 
al. 2001).  
 
1.8. Ras mutations in cancer 
The first oncogenes discovered in human cancer were Ras genes. 30 years of studies classified 
Ras genes as one of the most mutated driver genes in cancer. Although the first Ras isoform 
to be identified as an oncogene was H–Ras, further investigation showed that H-Ras had in 
fact the lowest frequency, whereas K-Ras had the highest (Stephen, Esposito et al. 2014). 
Despite the high degree of sequence homology between the four isoforms of Ras proteins, 
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over the years the idea of functional specificity for each isoform always became clearer. Many 
studies demonstrated that different types of tumours or developmental diseases showed a 
preference for one of the isoforms leading to a cell-type dependent transformation potential. 
Differences in post-translational modifications, subcellular localization and crosstalk with 
distinct transcriptional signalling pathways helped understanding that Ras isoforms acted 
separately and without overlapping with each other’s functions (Castellano and Santos 2011).  
27% of human cancer have missense gain-of-function in Ras genes at one of the hotspots G12, 
G13 and Q61. They count for 98% of all mutations found so far and result in a hyperactive Ras 
phenotype. In addition, dysregulation of GDP-GTP binding as well as loss of GAPs and constant 
GEFs activation increases Ras involvement in cancer development. As mentioned earlier, the 
mutation frequency of Ras isoforms is different with K-Ras being mutated in 85% of human 
cancers, N-Ras in 11% and H-Ras in only 4%. Numerous investigations showed evidence of 
cancer-specific mutation profiles where K-Ras was mutated in pancreatic ductal, lung and 
colorectal carcinomas; N-Ras mutations are found primarily in cutaneous melanoma while H-
Ras in head and neck squamous cell carcinoma (Table 1.) (Hobbs, Der et al. 2016).  
 
Table 1. Ras mutations in cancer (Hobbs, Der et al. 2016) 
Cancer Isoform Percentage 
Pancreatic ductal adenocarcinoma K 98 
Colorectal adenocarcinoma K 52 
Multiple myeloma K, N 43 
Lung adenocarcinoma K 32 
Skin cutaneous melanoma N 29 
Uterine carpus endometrioidcarcinoma K 25 
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Uterine carcinosarcoma K 14 
Thyroid carcinoma N > H 13 
Acute myeloid leukemia N > K > H 11 
Bladder urothelial carcinoma H, K > N 11 
Gastric adenocarcinoma K 10 
Cervical adenocarcinoma K 8 
Head and neck squamous cell carcinoma H 6 
 
 
1.9. Ras in cell cycle control  
1.9.1. Cell cycle control machinery  
Cell cycle is the essential mechanism of reproduction in living organisms. The major events of 
the eukaryotic cell cycle performed with high accuracy are chromosome duplication or DNA 
synthesis (S phase) and physical cell division or mitosis (M phase). One single cell cycle in a 
typical proliferating eukaryotic cell lasts an average of 24 hours, of which only 1 hour is 
occupied by mitosis and 10 to 12 hours by S phase. The remaining time is divided between 
two preparatory gap phases (G1 and G2) that precede S and M phase, respectively.  During 
this time, the cell grows in size, duplicates intracellular organelles and proteins and monitors 
the intra-/extracellular environment to ensure that all conditions are in favour of DNA 
synthesis or mitosis. G1 phase, usually longer than G2, is highly dependent, but not only, on 
extracellular stimuli. For example is case of limited growth factors availability, cells can delay 
G1 progression or even decide to exit the cell cycle and enter a resting state known as G0 
(quiescence) (Berridge 2014). The orderly progression through G1-S-G2-M is strictly 
controlled by a complex machinery whose main components are cyclins and cyclin-dependent 
kinases (CDKs). The cell cycle machinery is responsible for the transition through 3 crucial 
moments of the cell cycle: G1/S, G2 and spindle checkpoint. Progression through G1 and S 
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phase transition is supported and controlled by two complexes of cyclin-CDKs (cyclinD-
CDK4/6 and cyclinE-CDK2) in cooperation with the tumour suppressor pRB (retinoblastoma 
protein) (Weinberg 1995). Active pRB, hypophosphorylated state, is always bound to E2F 
transcription factor to repress its activity. pRB-E2F complexes are stable in quiescent cells and 
those exiting from mitosis. Mitogen–induced activation of cyclinD-CDK4/6 and cyclinE-CDK2 
complexes cause hyperphosphorylation of pRB, thus releasing E2F factors that promote 
expression of genes required for S phase entry (Dyson 1998, Coleman, Marshall et al. 2004). 
Once the G1/S checkpoint is crossed, the cell is committed to complete DNA synthesis and 
progress to the second gap phase. G2 phase and G2/M transition is further controlled by a 
CyclinB-CDK1 complex (Duronio and Xiong 2013). The cell cycle machinery has several layers 
of complexity and is highly orchestrated to execute progress through each phase of the cell 
cycle. A rather simplified view of its elaborate regulation is presented in figure 4.  
Despite the commitment to complete the cell cycle, in the event of any untoward anomaly, 
cells can activate both local control (for e.g., at the site of DNA replication factories) and global 
control via the next closest checkpoint to allow time for repair and restoration of the damage, 
failing which apoptosis is the chosen fate of the cell (Malumbres and Carnero 2003). As fail-
safe as these regulatory measures are, occasional errors that escape checkpoint surveillance 
may lead to uncontrolled cell proliferation and cancer. One of the most common 
characteristics in cancer development is dysregulation in G1 control (Sherr 1996), often 
connected to alterations of the tumour suppressor pRB like mutations and deletions that lead 
to loss of function of the protein. Although the dramatic dysregulation in cell cycle is a 
characteristic of every cancer, it is often a consequence and not sufficient to drive 
tumorigenesis in the first place. 
 
1.9.2. Ras-dependent cell cycle progression  
In 1985, Ras was identified for the first time as a key protein in cell cycle regulation. Ras 
function in cell cycle entry and progression was investigated in continuously proliferating cells 
and those emerging from quiescence. Neutralizing Ras activity via antibody microinjections 
or expression of inhibitory mutants stopped entry in S phase upon serum stimulation in 
cycling cells (Mulcahy, Smith et al. 1985, Stacey, Feig et al. 1991). Quiescent cells on the other 
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hand, were induced to proliferate only in the presence of oncogenic Ras and lack of growth 
factors (Feramisco, Gross et al. 1984, Mulcahy, Smith et al. 1985).  
 
The G1 to S phase transition was established to be Ras-dependent due to its ability to release 
E2F transcription factor from the inhibitory effect of pRB by hyperphosphorylating the latter 
(Mittnacht, Paterson et al. 1997, Peeper, Upton et al. 1997, Coleman, Marshall et al. 2004). 
However, pRB activity is also controlled by the PI3K pathway which upon inhibition can induce 
G1 arrest, unless pRB function is disrupted. Conversely, Ras activity but not Erk signalling, is 
still required in pRB-deficient cells to depart from quiescence and start proliferating (D'Abaco, 
Hooper et al. 2002). These findings suggested that under specific conditions Ras might have 
a different effector pathway. A second key player in this mechanism is cyclinD1 that in 
assembly with CDK4 or CDK6 directly hyperphosphorylate pRB. Many studies describe 
cyclinD1 expression being dependent on Ras signalling (Coleman, Marshall et al. 2004). They 
have different Ras requirements depending on the position of cells in the cycle. More 
specifically, cyclinD1 expression is dependent on Ras activity in resting cells re-entering the 
cycle (Filmus, Robles et al. 1994), while for actively proliferating cells Ras-induced cyclinD1 
occurs in the preceding G2 phase (Fig. 4) (Hitomi and Stacey 1999b). Ras protein exerts its 
effect on cyclinD1 transcription through two different signalling pathways: MAPK and PI3K 
pathways (Gille and Downward 1999). Erk-MAPK signalling facilitates cyclinD1 transcription 
(Suzuki, J et al. 2002), whereas PI3K the translation of cyclinD1 mRNA (Muise-Helmericks, 
Grimes et al. 1998). Yu et al. demonstrated that cyclinD1 is a prerequisite for Ras signalling to 
induce proliferation. They showed that cyclinD1-deficient mice did not develop breast cancer 
in presence of oncogenic Ras (Yu, Geng et al. 2001). 
Ras-mediated proliferation signals in G1 phase also alter p27 activity toward the end of G1 
phase by downregulating its overall expression and inducing binding with cyclinD1-CDK4 
complex. As a result, CyclinE-CDK2 disassociates from p27 by becoming active and inducing S 
phase entry (Aktas, Cai et al. 1997, Takuwa and Takuwa 1997, Weber, Hu et al. 1997). 
Somewhat contrary to this, p21 is observed to be marginally upregulated upon growth factor 
stimulation (Liu, Martindale et al. 1996, Bottazzi, Zhu et al. 1999). This effect might be 
explained with the role of p21 in stabilising cyclinD1-CDK4 complex (Cheng, Olivier et al. 
1999).  
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Figure 4. Ras activity during the cell cycle progression. 
A) Ras activity reaches two genuine peaks in the early and mid/late G1 phase, respectively. Late G1 phase is also 
characterized by a high CyclinD1 expression. For cells emerging from quiescence, Ras is required to induce 
cyclinD1 expression in G1 and G2 phase. In contrast, for actively cycling cells cyclinD1 expression is depend on 
Ras only during the preceding G2 phase. B) G1 to S transition is highly dependent on the hyperphosphorylation 
of the retinoblastoma protein (pRB) that releases the transcription factor E2F. Hyperphosphorylation of pRB is 
catalysed from the two cyclin-CDK complexes: cyclinD1-CDK2/4 and cyclinE-CDK2. Ras and PI3K signalling are 
two major pathways involved in the in controlling pRB cycling between its hypo- and hyper-phosphorylated 
forms, through cyclinD1. 
 
Despite the generally accepted mechanism, that Ras inactivates pRB by inducing a subsequent 
cyclinD1 expression and cyclinE activation, development of the mouse embryonic fibroblasts 
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(MEFs) carrying genetic ablation of the three Ras genes described a different expression 
pattern for the regulators of the cell cycle. Drosten et al. demonstrated that in the total 
absence of Ras protein (Rasless), MEF cells underwent significant changes in their morphology 
similar to senescent cells but did not express any specific marker (Drosten, Dhawahir et al. 
2010). Furthermore, Rasless cells could be held in culture for several weeks without activating 
apoptotic pathways. The special features of these Rasless MEFs were the normal expression 
levels of cyclinD1, its CDK associated complexes and cyclinE-CDK2. Nonetheless, 
phosphorylation of pRB did not occur, blocking the cells in a non-proliferating state. Only 
external downregulation of pRB could restore their proliferative capacity. These results 
indicated an important role of Ras proteins on controlling cyclin-CDK enzymatic activity 
mediated possibly through CDK inhibitors. shRNA (small hairpin RNA) library screen in Rasless 
cells highlighted the p53-p21Cip1 tumour suppressor axis as a new effector of Ras signalling 
(Drosten, Sum et al. 2014). Loss of either p53 or p21Cip1 expression induced proliferation in 
these cells presumably through a retroactive loop that sustained an active MAPK cascade 
independent from Ras (Drosten and Barbacid 2016). 
 
It is now well accepted that quiescent cells require growth factor stimulation not only to enter 
G1 phase, but also later until they cross the late G1 restriction point when cell become 
committed to progress through S phase (Pardee 1974). Injection of antibodies against Ras and 
cyclinD1 in NIH3T3 cells released from quiescence inhibited S phase entry at the same time. 
Interestingly, entry in S phase of cycling cells was blocked only when injection of anti-Ras 
antibodies was performed in mitosis preceding the current G1 phase. In contrast, injection of 
anti-cyclinD1 antibodies in G1 phase were able to significantly inhibit the next mitosis. These 
observations suggested distinct requirements of Ras activity and cyclinD1 throughout the cell 
cycle in actively proliferating NIH3T3 cells, where Ras activity is necessary in the preceding  
G2 phase and cyclinD1 during G1 (Hitomi and Stacey 1999b). Nonetheless, Ras was found to 
be constantly active throughout the cell cycle, while cyclinD1 in G1, G2 and M phase. 
Expression of oncogenic Ras as well as anti-Ras antibodies revealed that cyclinD1 was induced 
by Ras only in G2 phase and remained stable during the next G1 phase even in the absence 
of Ras activity (Hitomi and Stacey 1999a, Sa, Hitomi et al. 2002) .  
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1.10. Strategies to target Ras protein 
Direct and indirect approaches have been developed over the years to target oncogenic Ras 
(Figure 5). First trials were oriented in directly blocking Ras expression using gene silencing 
techniques. The use of RNA interference (RNAi) and antisense oligonucleotides (ODNs) 
revealed a higher specificity of RNAi for its target and significant growth inhibition for several 
types of cancer in cell lines and animal models. Nevertheless, RNAi-based therapies are very 
challenging because exogenous RNA can be recognized and destroyed by the host’s immune 
system. Additionally, it was shown that silencing of Ras was not enough to stop cancer 
development and eventually kill it.  
Figure 5. Schematic representation of the techniques used to target Ras protein. 
1: Microinjection of specific anti-Ras antibodies that bind and inhibit Ras activity. 2: Gene silencing methods to 
block Ras expression. 3: Introduction of external molecules to impair GTP-GDP regulation of Ras and terminate 
its signalling. 4: Utilization of various inhibitors against Ras downstream effectors. 5, 6: Altering post-
translational modifications to avoid Ras trafficking and attachment to the plasma membrane. 7: Transient 
transfection of dominant negative forms of Ras. 
 
An alternative way to inhibit Ras was to prevent post-translational modifications that 
facilitate Ras translocation and association to the plasma membrane. Two groups of enzymes 
were targeted: FTIs and GGTIs. Failure for this strategy was due to the lack of Ras specificity 
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and clinical activity. Despite many unsuccessful trials, several groups tried developing small 
molecules that could permanently bind to inactive Ras, impairing GTP-GDP regulation and 
subsequently terminate signal transduction of Ras-Raf-MAPK pathway. In addition, 
interfering with Ras interaction with its GEFs was seen as a blocking option. One of the major 
strategies used to interfere with Ras signalling was targeting its downstream effectors. Some 
of the investigational drugs used to target Ras effectors are listed in table 2 (adapted from 
Takashima et al. 2013). The discovery and development of new drugs that target Ras-effectors 
is the most promising therapy so far, even though cancer cells gained resistance to some of 
the drugs (Takashima and Faller 2013). 
Table 2. Some of the drugs used to target Ras effectors 
Target  protein Name of the drug 
MEK1/2 
Trametinib 
Selumentinib 
Pimasertinib 
Refamentinib 
TAK-733 
AS703988 
Mutant B-Raf 
Dabrafenib 
Regorafenib 
LGX818 
RO5212054 
ARQ736 
Class I PI3K and mTORC1/2 
PF-04691502 
PKI-587 
PF-05212384 
XL765 
GSK2126458 
DS-7423 
  Introduction 
 
21 
 
mTORC1/2 
CC-223 
ME-344 
AZD2014 
OSI-027 
AKT1/2/3 
GSK2110183 
GDC-0068 
AZD5363 
ARQ092 
GSK2141795 
 
Another tool in cancer gene therapy was the use of dominant active and negative Ras 
mutants. The most frequent dominant active mutants are RasG12V and RasQ61L, while 
RasS17N is the most popular dominant negative mutant. Ras mutants mainly served to shed 
light on its role in the signalling transduction pathways and identification of downstream 
effectors. As mentioned in the previous section, Ras was identified as a crucial player in 
regulation cell proliferation. First investigations were performed by Stacey’s group and made 
use of anti-Ras antibodies microinjected into single cells. 
A general limitation of the strategies described is that they are highly time-dependent and 
from a technical point of view the time required to perform any experiment is on the range 
of 12-24 hours, sometimes even 48 hours.  
 
1.11. Protein translocation and dimerization importance in signal transduction 
Protein-protein interaction is the basis of all signal transduction networks. Depending on the 
extracellular stimuli and type of the cell, the biological outcome of these interactions varies. 
Regardless of this, protein interaction can be stable or dynamic like phosphorylation and 
nucleotide exchange. Two or more proteins can be engaged at the same time in every step of 
the signal transduction. One of the interactions during the transmission of extracellular 
signals to the nucleus is protein dimerization. Optimal proximity and correct orientation are 
two important factors that can accelerate the reaction. Sometimes this is not enough because 
the viscosity of the intracellular environment affects the speed of the dimerization process, 
usually by slowing it down. Therefore, another stimulus or mechanism that induces the 
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dimerization effectively helps the interaction. The most frequent example is the EGF cell 
surface receptors. EGFRs consist of three domains: extracellular, transmembrane and 
intracellular domain. Binding of the epidermal growth factor on the extracellular domain 
induces the dimerization of two receptors followed by their activation and further 
transmission of the signal (Klemm, Schreiber et al. 1998).  
Putyrski and Schultz showed that a crucial event during the dimerization is the translocation 
of the proteins (Putyrski and Schultz 2012). One common example of the importance of 
protein translocation in signal transduction is the Akt and PDK1 interaction, which after being 
recruited to the plasma membrane exert their function by phosphorylating each other and 
forwarding the signal to the next step of the cascade (Ding, Liang et al. 2010). The 
translocation to the plasma membrane is facilitated by the second messenger PtdIns(3,4,5)P3 
(phosphatidylinositol 3,4,5-trisphosphate), that both of them recognize. Akt and PDK1 kept 
phosphorylating each other even when they were brought together in an artificial way in the 
cytosol. In contrast to other techniques like RNAi or transfection when the result of the 
manipulation is visible after 12 to 72 hours (Ouyang and Chen 2010, Raina and Crews 2010), 
the translocation took place within seconds affecting the outcome of the pathway. These 
observations led to the development of new and more sophisticated methods that induce 
intracellular translocation as a faster way to alter signal transduction.  
 
1.12. Rapamycin/Rapalog induced translocation 
Understanding the mechanism of action of immunosuppressive drugs like rapamycin gave the 
first hint for the development of induced dimerization systems. Rapamycin is a potent, 
selective, allosteric inhibitor of the TORC1 complex by binding both components of the 
complex: protein kinase TOR and FKBP12 (FK506 binding protein of 12 kDa). The latter is the 
first to interact with rapamycin following which the rapamycin-FKBP12 complex can bind to 
TOR (Choi, Chen et al. 1996, Liang, Choi et al. 1999).  
Based on this mechanism, FKBP12 and FRB (FKBP and rapamycin binding site of TOR) were 
fused with two other proteins to induce rapamycin-dependent gene expression in cells 
(Rivera, Clackson et al. 1996). For many years, the rapamycin-inducible FKBP-FRB interaction 
was used to specifically manipulate protein activity localised at the plasma membrane like G 
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proteins, enzymes involved in metabolism, receptor tyrosine kinases, protein kinases and 
adaptor proteins. 
The effects of rapamycin application in cultured cells were overlooked only in case of short 
time experiments. Otherwise, non-toxic rapalogs (synthetic analogues of rapamycin) 
administration was recommended to avoid negative effects of rapamycin on cell growth, 
proliferation and apoptosis (Wullschleger, Loewith et al. 2006, Zoncu, Efeyan et al. 2011). The 
rapalogs design was based on the “bump-and-hole” scheme (Clackson 1998, Clackson 2008). 
The FRB-binding site of rapamycin (the “bump”) was modified in order to lose its affinity to 
recognise and bind the wild type FRB. On the other hand, the rapamycin-binding pocket (the 
“hole”) was enlarged to fit the rapalog as well as to impair interaction with rapamycin itself. 
Among the several rapalogs produced, the most used is AP21967. Despite all the advantages 
that this new technique introduced, there are some limitations. Among them is the high 
affinity between rapamycin or rapalogs and their target proteins that makes the reversibility 
of the heterodimerization system a difficult task to accomplish. Up to date, only few papers 
have reported a dissociation of the fusion proteins in the order of hours (Karpova, Tervo et 
al. 2005). It is worth mentioning, that there are no readymade fusion proteins meaning that 
every lab must clone its own system which is fairly challenging. Moreover, both fusion 
proteins should be stably introduced into the desired cell line and further checked for their 
correct localization and proper functionality (Putyrski and Schultz 2012).   
 
1.13. Use of the dimerization system to study small GTPases  
The induced heterodimerization system has been very useful in investigating the specific role 
of small GTPases due to its rapid perturbation on the functionality of its target protein (Inoue, 
Heo et al. 2005). Many groups focused their work on the activation mechanism and function 
of several members of the Rho family such as Rac and Cdc42. Castellano et al. studied Rac1 
role in lamellipodia formation and membrane raffling (Castellano and Chavrier 2000, 
Castellano, Montcourrier et al. 2000). For this purpose, they used a rapamycin-induced 
translocation of FRB-bound Rho GTPase (Rac1) towards the FKBP-conjugated transmembrane 
receptor and were able to demonstrate that Rac signalling was important in remodelling the 
plasma membrane, thus allowing particle internalization. Since, their translocation strategy 
was not sufficient to prove their point, other techniques like antibody-coated beads were 
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used to support the heterodimerization system. Few years later, Inoue et al. developed an 
improved system able to directly target Rho GTPases in a faster way (Inoue, Heo et al. 2005). 
The key to their success was designing several fusion constructs with different orientations of 
the proteins and numbers of FKBP domains. In addition, they switched the FKBP and FRB 
domains between the two fusion proteins and used the rapamycin analog, AP21967 (iRap). 
By testing all pair’s combinations for the iRap-induced lamellipodia extension, the best results 
were obtained by the heterodimerization of the FRB-coupled membrane-bound fusion 
protein with the FKBP- bound Rac1 fusion construct.  
Komatsu et al. made further use of this system to activate Ras at distinct intracellular 
locations. Both fusion proteins were modified to bind and/or act at specific cellular 
compartments: plasma membrane, mitochondria, endoplasmic reticulum and lysosome. 
Addition of the chemical iRap induced dimerization of the fusion proteins in all organelles 
without differences (Komatsu, Kukelyansky et al. 2010).  
 
1.14. Inducible system to switch on and off Ras  
Based on the prototypic heterodimerization kit of Ariad/Clontech technologies (Inoue, Heo et 
al. 2005), our lab developed an inducible FKBP-FRB system capable of altering Ras activity by 
turning it off. The FKBP-coupled fusion protein is stably associated to the plasma membrane 
through the hvr-CAAX motif (hypervariable region) and from now on will be referred to as the 
‘anchor unit’. The FRB-coupled fusion protein included a RasGAP (NF1, Neurofibromin1) that 
catalyses GTP expenditure to inhibit Ras function, when positioned in proximity to GTP-loaded 
Ras. In the absence of a specific stimulus, this fusion protein is deliberately designed to be 
diffusely expressed in the cytosol and will be referred to as the ‘effector unit’. A simple scheme 
illustrates the principle of RasOFF heterodimerization system in figure 6.   
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Figure 6. Principle of the induced RasOFF heterodimerization system. 
FKBP-coupled anchor unit is bound to the plasma membrane through the hvr of K-Ras, while the FRB-coupled 
effector unit is spread throughout the cytosol. Upon heterodimerizer (iDim) addition, the effector unit 
translocates toward the membrane-bound unit and is able to inhibit the activity of endogenous Ras protein.  
 
The chemical dimerizer used in our case is the commercially available rapamycin analogue, 
AP21967 (iDim). Administration of the latter induces the translocation of the effector unit 
toward the plasma membrane bringing NF1 in close proximity with endogenous Ras. 
Consequently, Ras should be turned off.  
This heterodimerization system targets Ras in a rapid and less invasive way for the cell and 
provides a new, more elegant technique to investigate the function of Ras at particular stages 
of the cell cycle. 
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2. Aim of the work  
 
Ras is a monomeric membrane-associated GTP-binding protein that fluctuates between two 
distinct conformational structures defining its state as active (GTP-loaded) or inactive (GDP-
loaded). Sustained in its active state, Ras becomes oncogenic, inducing uncontrolled cell 
proliferation and cancer development. In fact, Ras mutations are among the most common, 
found in nearly 30% of human cancers, yet the precise nature and magnitude of Ras signalling 
in the temporal control of cell proliferation is only partly understood. 
Seminal reports have linked Ras activity with cyclinD1 expression to enable cell cycle 
progression depending on the proliferative context of cells. Primarily due to the lack of 
appropriate experimental approaches, very little is known about the involvement of Ras 
signalling at precise times during particular cell cycle phases that determines the fate of 
proliferating cells.  
In this thesis work, we aimed to gain insight into the importance of Ras signalling with respect 
to progression through different cell cycle stages using a unique heterodimerization system 
allowing rapid inactivation of Ras. The major experimental aims were as follows: 
 
1. Validating the utility and extent of application of the heterodimerization system in 
studying dependent control of cell proliferation and cell cycle progression. 
2. Establishing a suitable cell model amenable to efficient synchronisation, while also 
stably expressing the two-unit heterodimerization system for Ras inactivation. 
3. Functional dissection of the role and requirement of Ras signalling through the cell 
cycle by abrogating its activity at specific phases. 
4. Elucidating effector pathways downstream of Ras that exert its function in cell cycle 
control. 
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3. Materials and methods 
 
3.1. Materials 
Table 3. Cell lysis and flow cytometry buffers 
 
Cell lysis buffers 
 
 
Composition 
 
Ras activity lysis buffer 
50 mM HEPES pH 7.5 
150 mM NaCl 
5 mM MgCl2 
1 mM EGTA 
1% NP-40 
 
Freshly added: 
100μM GDP 
2mM DTT 
25μg/ml purified GST-Raf1-RBD 
RIPA lysis buffer 
 
50mM TRIS-HCl pH 8.0 
150mM NaCl 
5mM MgCl2 
1% Nonidet P-40 
0.5% Deoxycholate 
0.1% SDS 
Protease and phosphatase 
inhibitors 
freshly supplemented from frozen stocks 
Protease inhibitors 
42 mM Pefabloc 
2 μM Leupeptin 
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100 μM PMSF 
1.5 μM Pepstatin A 
phosphatases inhibitors 
100 μM Sodium Vanadate 
3.4 nM Microcystin 
1 μM β-Glycerophosphate 
Reaction buffer for homemade 
EdU-ClickiT cell cycle analysis 
50mM Tris HCl pH 7.6 
150mM NaCl 
 
Table 4. SDS-PAGE buffers 
 
SDS-PAGE buffers 
 
 
Composition 
 
10 x electrophoresis running buffer 
250 mM Tris 
2 M Glycin 
35 mM SDS 
2 x Laemmli buffer 
20% Glycerol 
4% SDS 
10% 2-Mercaptoethanol 
0.02% Bromophenol blue 
124 mM Tris pH 6.8 
5 x Laemmli buffer 
33% Glycerol 
5% SDS 
25% 2-Mercaptoethanol 
0.02% Bromophenol blue 
85 mM Tris pH 6.8 
Separating gel buffer 
2 M Tris 
pH 8.8 
Stacking gel buffer 0.5 M Tris 
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pH 6.8 
Coomassie staining buffer 
0.5% Coomassie Brilliant Blue R-250 in 
absolute ethanol 
mix 1:1 with 20% acetic acid 
Destaining buffer 
10% Acetic acid 
25% Ethanol 
 
Table 5. Western blotting buffers 
 
Western blotting buffers 
 
 
Composition 
 
Transfer buffer 
48 mM Tris 
39 mM Glycin 
0.037% SDS 
15% Methanol 
pH 10 
10 x TBS-Tween 
100 mM Tris 
1 M NaCl 
1% Tween 20 
pH 7.6 
Stripping buffer 
100 mM 2-Mercaptoethanol 
62.5 mM Tris 
2% SDS 
pH 6.7 
 
Antibody solutions: 
 
Primary antibody solution 
Secondary antibody solution  
 
 
 
1%BSA in 1xTBS-Tween with 0.02% NaN3 
1%BSA in 1xTBS-Tween 
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Table 6. Kits 
 
Name 
 
 
Vendor 
 
 
Catalogues No. 
 
Click-iT® Plus EdU Alexa Fluor® 647 Flow 
Cytometry Assay Kit 
Molecular Probes™ C10634 
Pierce® BCA Protein Assay Kit Thermo Scientific TM 
#23225 
#23227 
 
Table 7. Cell culture reagents 
 
Name 
 
 
Vendor 
 
 
Catalogue No. 
 
A/C Heterodimerizer Clontech 635057 
Accutase Sigma-Aldrich Co. LLC. A6964 
Collagen Sigma-Aldrich Chemie GmbH C7661 
DMEM Sigma-Aldrich Co. LLC. D6429 
DMSO Sigma-Aldrich Chemie GmbH D2650 
EGF Peprotech AF-100-15 
FCS Biowest LLC S1810-050 
GlutaMax Gibco® by Life technologies 35050-038 
HEPES AppliChem GmbH A1069,0500 
LY294002 Enzo Life Sciences BML-ST420 
MEM Amino acids PAA Laboratories GmbH 11140-035 
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Nocodazole Sigma-Aldrich Chemie GmbH M1404 
OptiMEM medium Invitrogen, life technologies, 31985-070 
Penicillin – Streptomycin Sigma-Aldrich Chemie GmbH P0781 
Polyethylenimine (PEI) 
branched 
Sigma-Aldrich Chemie GmbH 40,872,7 
Puromycin Sigma-Aldrich Chemie GmbH P8833 
RO-3306 Sigma-Aldrich Chemie GmbH SML0569 
Sodium pyruvate PAA Laboratories GmbH S11-003 
Thymidine Sigma-Aldrich Chemie GmbH T1895 
Trypsin-EDTA Gibco®by Life technologies 25300-045 
U0126 (MEK inhibitor) Enzo Life Sciences BML-EI282 
 
Table 8. Primary antibodies and conjugates 
 
Name 
 
Vendor 
 
Catalogue 
No. 
 
Application 
 
Dilution 
Akt 
Cell Signaling 
Technology® 
9272 Western blot 1:2000 
Anti-pan-Ras C-4 CALBIOCHEM® sc-166691 Western blot 1:500 
Cyclin D1 (92G2) 
Cell Signaling 
Technology® 
2978 Western blot 1:1000 
EGF receptor 
Cell Signaling 
Technology® 
4267 Western blot 1:2000 
H-Ras (C-20) 
Santa Cruz 
Biotechnology® 
sc-520 Western blot 1:1000 
K-Ras (F234) 
Santa Cruz 
Biotechnology® 
sc-30 Western blot 1:1000 
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mTOR (human FRB 
Domain) 
Enzo® Life Sciences 
GmbH 
ALX-215-
065 
Western blot 1:1000 
N-Ras (F155) 
Santa Cruz 
Biotechnology® 
sc-31 Western blot 1:500 
p44/42 MAPK 
(ERK1/2) (137F5) 
Cell Signaling 
Technology® 
4695 Western blot 1:1000 
p-EGF Receptor 
(Y1068) 
Cell Signaling 
Technology® 
2236 Western blot 1:1000 
pErk (E-4) 
Santa Cruz 
Biotechnology® 
sc-7383 Western blot 1:1000 
phospho-Akt (S473) 
Cell Signaling 
Technology® 
9271 Western blot 1:2000 
phospho-Akt 
(Thr308) 
Cell Signaling 
Technology® 
9275S Western blot 1:1000 
phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
(E10) (Alexa Fluor® 
647 Conjugate) 
Cell Signaling 
Technology® 
4375 Flow cytometry 1:50 
RalA 
BD Transduction 
Laboratories™ 
610221 Western blot 1:1000 
Rap1 
BD Transduction 
Laboratories™ 
610195 Western blot 1:1000 
RB2 Clone 10 
BD Transduction 
Laboratories™ 
610261 Western blot 1:1000 
α-GFP 
Ian A. Prior, University 
of Liverpool 
 Western blot 1:1000 
α-RFP 
Ian A. Prior, University 
of Liverpool 
 Western blot 1:1000 
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Table 9. Secondary antibodies 
 
Antibody 
 
 
Source 
 
 
Dilution 
 
 
Application 
  
 
Vendor 
 
HRP-anti mouse goat polyclonal 1:10000 Western Blotting KPL® 
HRP-anti rabbit goat polyclonal 1:10000 Western Blotting KPL® 
HRP-anti sheep rabbit polyclonal 1:10000 Western Blotting 
Santa Cruz 
Biotechnology® 
 
Table 10. General chemicals 
 
Name 
 
 
Vendor 
 
 
Catalogue No. 
 
2-Mercaptoethanol Fluka Biochemika 63690 
4% Glutathione Agarose Jena Bioscience AC-210-CSTM 
Acetic acid Carl Roth GmbH & Co. KG 3738.5 
Ammonium persulphate (APS) SERVA Electrophoresis GmbH 13375 
bisBenzimide H 33342 
trihydrochloride (Hoechst33342) 
Sigma-Aldrich Chemie GmbH B2261 
Bovine serum albumin (BSA) PAA Laboratories GmbH K41-001 
Bromophenol blue Carl Roth GmbH & Co. KG A512.1 
Calcium chloride (CaCl2) AppliChem GmbH A4689,0250 
Coomassie Brilliant Blue G-250 
Carl Roth GmbH & Co. KG 
Fluka Biochemika 
9598.1 
27815 
DAPI Molecular Probes Invitrogen, D1306 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Chemie GmbH D2650 
Dithiothreitol (DTT) AppliChem GmbH A2948,0010 
EdU (5-Ethynyl-2’-deoxy-uridine) Jena Bioscience CLK-N001 
Ethanol Carl Roth GmbH & Co. KG K928 
Ethylene glycol tetraacetic acid (EGTA) AppliChem GmbH A0878,0025 
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Ethylenediaminetetraacetic acid 
(EDTA) 
Carl Roth GmbH & Co. KG 8043.2 
Glycerol Carl Roth GmbH & Co. KG 3783.2 
Glycine PUFFERAN® Carl Roth GmbH & Co. KG 3908.3 
GST–Raf-1-RBD In house  
GST-RalBD In house  
Guanosine diphosphate (GDP) Sigma-Aldrich Chemie GmbH  
Isopropanol Carl Roth GmbH & Co. KG 6752.4 
Leupeptin-hemisulphate AppliChem GmbH A2183, 0025 
Magnesium chloride (MgCl2) Carl Roth GmbH & Co. KG HN03.1 
Methanol Carl Roth GmbH & Co. KG 3880.2 
Microycystin-LR Enzo Life Sciences GmbH  
N,N,N’,N’-
Tetramethylethylenediamine (TEMED) 
Serva Electrophoresis GmbH 35930 
Nonylphenylpolyethylenglycol 
(Pietenpol and Stewart)-40 
Merck KGaA 492016 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific Inc. 26616 
Paraformaldehyde Sigma-Aldrich Chemie GmbH 158127 
Pefabloc SC®(AEBSF hydrochloride) AppliChem GmbH A1421,0500 
Pepstatin A AppliChem GmbH A2205,0025 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich Chemie GmbH P7626 
Picolyl azide sulfo-Cy5 Jena Bioscience CLK-1177 
Potassium acetate Carl Roth GmbH & Co. KG 4986.1 
Potassium chloride (KCl) Carl Roth GmbH & Co. KG 6781.1 
Propidium Iodide EMD Chemicals, Inc. 537059 
RNase A from bovine pancreas Roche Diagnostics GmbH 70297721 
Rotiphorese® Gel 30 
30 % Acrylamide/Bis-acrylamide 
(37.5:1) 
Carl Roth GmbH & Co. KG 3029.1 
Sodium chloride (NaCl) Carl Roth GmbH & Co. KG 3957.2 
Sodium Deoxy cholate Sigma-Aldrich Chemie GmbH D6750 
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Sodium Deoxycholate Sigma-Aldrich Chemie GmbH D6750 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich Chemie GmbH A3942,1000 
Sodium hydroxide (NaOH) Sigma-Aldrich Chemie GmbH 9356.1 
Sodium orthovanadate Sigma-Aldrich Chemie GmbH S6508 
Sodium-β-glycerophosphate SERVA Electrophoresis GmbH  
Tris ultrapure AppliChem GmbH A1086,5000 
Triton® X-100 Carl Roth GmbH & Co. KG 6683.1 
Tween® 20 SERVA Electrophoresis GmbH 3747.0 
Western Lightning ECL, Enhanced 
Chemiluminescent Substrate 
PerkinElmer 
0RT2655 
0RT2755 
Whatman filter paper Bio-Rad Laboratories Inc.  
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3.2. Methods  
3.2.1 Cell lines and treatments 
Cervical cancer (HeLa) cells, Human Embryonic Kidney 293 T (HEK293T) cells were originally 
provided by Yan Cui, Leibniz Institute on Aging – Fritz Lipmann Institute (Capon, Seeburg et 
al.), Jena, Germany. HEK293T cells (kindly provided by Yan Cui, FLI, Jena, Germany) DMEM/F-
12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12) supplemented with 10% FCS.  
Stably transduced HeLa#1#7 cells generated from the former master student, Stephanie 
Bresan, were cultured at 95% humidity, 37°C and 5% CO2 atmosphere in DMEM (Dulbecco’s 
modified Eagle’s medium) supplemented with 10% FCS. 
T98G glioblastoma cells kindly provided by Dr. Helmut Pospiech (FLI, Jena, Germany), were 
cultured in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% FCS, 1x L-
Glutamax, 1mM Sodium pyruvate and 1x NEAAs (non-essential amino acids) under standard 
conditions (95% humidity, 5% CO2, 37°C). Cells were split 3-4 times per week when they 
reached 80% confluency.  
Synchronized cells (see section 5) were treated with the heterodimerizer or inhibitors as 
indicated in the results section. In the cases that the samples were prepared for western blot 
analysis, the release media was supplemented with 10ng/ml EFG. In case the release occurred 
in the presence of the heterodimerizer or inhibitors, the latter was added to the cells starting 
from the last 30 min of the synchronization.  
 
3.2.2. Transfection procedure 
3.2.2.1 Transient transfection 
Transient expression of the heterodimerization units within cells was achieved using 
polyethylenimine (PEI), a stable cationic polymer, as a transfection reagent. One day before 
being transfected, cells were seeded in a 6-well plate or glass-bottomed dish depending on 
whether they would be harvested for western blot or used for confocal microscopy 
experiments. The transfection is efficient if performed at a cell density of 50-60% confluency. 
Via a serial dilution in pre-warmed reduced serum media OptiMEM (1:20 and 1:25), a PEI 
solution was prepared with a final concentration of 20ng/ml. In parallel, 1-2µg of plasmid DNA 
was dissolved in 250µl of OptiMEM. In the next step, an equal volume of the PEI and DNA 
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solution (250µl each) were mixed and allowed to complex for 20-30 minutes at room 
temperature. It is important to mention that PEI must be added to the DNA solution and not 
the other way around. During this time, the media of the cell was replaced with 1ml of 
OptiMEM. After the incubation time is over, 500µl of PEI/DNA mixture were added to each 
well while gently swirling the plate by a slow hand rotation. Plates were incubated under 
standard conditions and after 4-6 hours media was exchanged with 2ml of DMEM with 10% 
FCS. The next day (24 hours post transfection) cells were checked under the microscope for 
GFP or mCherry expression and afterwards proceeded for western blotting or LSM 
measurements.  
 
3.2.2.2 Lentiviral transduction 
The stable expression of our constructs of interest in HeLa or T98G cell lines was achieved 
through a lentiviral transduction using the third-generation of lentiviral vectors. In this case, 
our plasmid DNA introduced in a lentiviral expression vector (pCDH) was co-transfected with 
two packaging vectors (pMDL-g and pRSV-g) and an envelope vector pVSV-g.  
Production of the infectious lentiviral particles was performed in HEK293T cells. The latter 
were seeded in 100mm dishes at a density of 40-50% confluency (1.5-2 x 106 cells/dish). The 
next day a PEI transfection was performed on HEK293T cells, but with a modified DNA mixture 
containing 4 plasmids. Taking into account the limited amount of DNA that can be introduced 
in one single cell, the correct ratio between the four plasmids is of critical importance. 
Following this argument, the DNA solution for one reaction contained 8µg of expression 
vector and 14µg of lentiviral vectors mix dissolved in 1.5ml of OptiMEM. The ratio between 
pVSV-g, pRSV-g and pMDL-g was 1:2.4:3.6. After 25-30 minutes of incubation at room 
temperature, the PEI/DNA mixture was distributed at 3ml per dish and placed back in the 
incubator. The following procedure is the same as described in the previous section.  
The same day, the target cells (HeLa or T98G) were seeded in 6-well plates at 30% confluency. 
The first transduction of the lentiviral particles was performed 24-48 hours after HEK293T 
cells were transfected. The supernatant of the transfected HEK393T cells was collected and 
filtered through a 0.4µM filter. Afterwards the viral particles were concentrated using Amicon 
Ultra-15 centrifugal filters via a centrifugation step of 10-13 minutes at 4000xg, at room 
temperature. The concentrated viral particles were mixed with 1x polybrene (8µg/ml) and 
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then equally distributed in the 6-well plate. As a final step the target cells underwent a 
centrifugation round for 1 hour at 500xg, at room temperature. The transduction step was 
repeated up to three times every 24 hours while cells were kept under standard conditions.  
After 24 hours from the last transduction step, cells were selected with puromycin for one 
week. Only cells that had efficiently incorporated in their genome our gene of interest would 
be resistant to the antibiotic. Depending on the cell line, the final concentration of puromycin 
in the media was 2µg/ml for HeLa cells and 1.5µg/ml for T98G cells. However, antibiotic 
selection is not enough to have a pure culture with only double positive cells. This is due to 
the gain of antibiotic-resistance that cells develop after some time of being exposed to 
relatively low concentrations of the antibiotic. The concentration used is high enough to 
induce apoptosis in not transduced cells and to allow survival of the transduced one.   
 
3.2.3. Generation of homogeneous cultures 
3.2.3.1 FACS Sorting of double positive cells 
FACS sorting of the double positive cells was done with the help of Yvonne Schlenker, at the 
FACS facility at the Uniklinikum Jena. Cells were washed once with 5ml PBS and then detached 
from the flask with 2ml Accutase, a more gentle solution for cells than Trypsin, for 2-4 minutes 
of incubation under standard conditions. Cells were further mixed with 5-10ml of PBS, 
spinned down for 5 min at 300xg and re-suspended in 3ml of PBS supplemented with 10% 
FCS. Preparation of suspended cells was done shortly before being sorted. Three controls 
were required for correct gating of the double positive cells: wild type cells and two single 
positive cells each expressing one of our constructs, the GFP- or mCherry-bound unit. Sorted 
cells first collected in growth media, were washed once with PBS + 10% FCS before being 
transferred in a T25cm2 flask. They were kept in the presence of antibiotics, Penicillin-
Streptomycin, for few days after sorting to avoid contaminations.  
 
3.2.3.2. Limiting dilution and clonal cultures 
Sorted T98G#1#7 cells were trypsinized, counted using a Neubauer chamber and further 
diluted to 1-2 cells/ml. They were seeded in 96-well plate and followed for several weeks. 
Media containing 1.5μg/ml puromycin was renewed every 2-3 days. Before cells reached 90% 
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confluency they were transferred into 12-well plates and later on in T25cm2 flasks. Meanwhile 
they were also checked for the presence of the constructs under the microscope.  
 
3.2.4. Laser scanning microscopy (LSM) 
Confocal laser scanning microscopy is a microscopic technique that provides images with high 
contrast and resolution by scanning the sample point by point or at multiple points at a time. 
The instrument has the ability to assemble the information only from an in-focus plane and 
rule out any signal coming from out-of-focus planes.  
In order to obtain high quality images, cells were seeded in glass-bottomed dishes that were 
previously coated with collagen. Only the glass part of the dish was covered with sterile 
collagen solution (100μg/ml) and incubated for 1-2 hours at room temperature. After the 
collagen was recollected, the glass-bottomed dishes were washed twice with sterile water 
and allowed to thaw for 2 hours at room temperature. Collagen-coated glass-bottomed 
dished could be stored at 4OC.  
To investigate the heterodimerizer-induced translocation of the effector unit toward the 
anchor unit, HeLa or T98G cells expressing both units were seeded in collagen-coated glass-
bottomed dishes at 30% confluency. The next day media was exchanged with fresh growth 
medium supplemented with 25mM HEPES. Images were taken using Zeiss LSM 510 inverted 
laser scanning microscope (LSM) and C-Apochromat x63 water immersion objective lens. 
Excitations of the fluorophores was achieved with Ar 488nm and HeNe 543nm lasers for EGFP 
and mCherry respectively. Addition of the heterodimerizer was performed on stage, without 
touching the glass-bottomed dish and images were captured at the indicated times (see 
Results). Images were further process using ZEN software.  
 
3.2.5. Synchronization techniques  
Cell cycle synchronization techniques are used to emphasise the result of a specific treatment 
in cycling cells. In our case, cells were synchronized cells in 4 different moments of the cell 
cycle: in G0 (resting state/quiescent) phase, G1/S border, G2/M border and in mitosis (M 
phase).  
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T98G cells were induced to exit the cell cycle and enter G0 after 72 hours of serum starvation. 
230˙000 cells per 60mm dish were seeded and the next day growth media was exchanged 
with starvation medium after washing them three times with DMEM without serum. The 
starvation medium was supplemented only with 0.15% FCS which is enough to keep cells alive 
and not die during the 72 hours of starvation. Stimulation of quiescent cells to re-enter cell 
cycle was achieved by replacing the starvation with release media. The latter is a 1:1 ratio 
combination of growth with conditioned medium. 
G1/S synchrony of T98G cells (seeded 200˙000 cells/60mm dish) was obtained through 24 
hours of treatment with 2mM thymidine. The presence of the latter in the cell blocks DNA 
synthesis by inhibiting a necessary enzyme for this process, ribonuclease reductase. As a 
result cells progress throughout G1 phase, but are not able to start S phase. Release in the 
cell cycle was possible after removing the inhibitor through three steps of washings with PBS 
and by adding complete release medium (1:1 ratio of growth and conditioned media).  
A double block with thymidine and RO3306 induced accumulation of cells in late G2 phase. 
Seeded cells (200˙000 cells/60mm dish) were treated with 2mM thymidine for 24 hours. After 
being washed 3 times with PBS, cells were released for 3 hours in release media and further 
incubated with 10μM RO3306 for 14 hours. RO3306 is a quinolinyl thiozoline derivate that 
inhibits the formation of cyclinB-CDK1 complex by binding the latter and leading to a G2 phase 
block. Removal of the inhibitor followed by 3 washing steps with PBS and addition of the 
release media induced cell cycle progression.  
Synchronization in mitosis of HeLa cells was achieved by a double block with thymidine and 
nocodazole. The procedure is almost the same as in the previous paragraph with the only 
difference that RO3306 is substituted with nocodazole (100mg/ml). Nocodazole inhibits 
microtubule polymerization and stops mitotic spindle formation. For the release of HeLa cells 
only normal growth media (DMEM + 10% FCS) was used.  
 
3.2.6. Ras activity assay 
A Ras pulldown assay was performed to detect GTP-loaded levels of the protein for each 
timepoint. The cell extract was prepared by lysing through scraping cells in ice-cold lysis buffer 
supplemented with protease inhibitors, phosphatase inhibitors, DTT, GDP and GST-RBD (Ras-
binding domain of Raf 1) after being washed once with ice-cold PBS. Depending on the dish, 
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the amount of the lysis buffer used varied from 850μl to 1.3ml for a 60mm and 100mm dish 
respectively. The complex GTP-loaded Ras-GST-RBD is extracted from the whole cell lysate 
through glutathione-sepharose beads that are added to the cell lysate after 20 minutes of 
centrifugation at 4OC at 13000rpm and incubated for at least 30 min at 4OC with mild rotation. 
Only for experiments performed in HeLa cells, the precipitate at this stage was dissolved in 
50μl of 2x Laemmli solution and boiled for 5 min at 95OC. This is the nuclear extract that was 
used later to detect cyclinD1 expression. Following incubation, samples were briefly 
centrifuged (10 seconds at 13˙300rpm) and 400μl of supernatant mixed with 100μl of 5x 
Laemmli solution were transferred in new vials. This represents the total cell lysate samples, 
including the total load of Ras protein. The RasGTP-bound beads were sequentially washed 
twice with 750μl of lysis buffer in absence of inhibitors. Dissociation of the complex GTP-
loaded Ras-GST-RBD was obtained after treatment of the samples with 40μl of 2x Laemmli 
solution. Samples were further processed for western blotting. 
 
3.2.7. Preparation of whole-cell lysates using RIPA buffer 
Treated T98G cells were washed once with ice-cold PBS and further lysed directly in ice-cold 
RIPA buffer, 850μl for 60mm dishes, to obtain cyclinD1 and pRB2 expression levels. Samples 
were cleared by spinning for 20 minutes at 13˙300rpm, at 4OC and 800μl of the supernatant 
mixed with 200μl of 5x Laemmli buffer were transferred in new eppendorf tubes.  From the 
remaining supernatant, 5μl were used for protein quantification. At this point, lysates can be 
stored at -20OC or processed for western blotting.  
 
3.2.8. Protein quantification 
Protein concentrations were quantified using Pierce BCA Protein Assay Kit following the 
manufacturer’s instructions. The assay was performed in a 96-well plate and the absorption 
measured using a spectrophotometer at 570nm. The final concentrations of the samples were 
calculated using a known standard BSA concentration range developed in parallel. 
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3.2.9. SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed in 
vertical electrophoresis system, using 40-70μg proteins. Depending on the molecular weight 
of the analysed protein, 7.5% and 12.5% polyacrylamide separating gels were used. Protein 
separation was achieved after approximately 3h of run in SDS buffer at a constant current of 
20-40mA. 
 
3.2.9.1. Western blotting and immunodetection of immobilized proteins 
Except for the GST-Raf1-RBD whose visualization was through Coomassie staining, all other 
resolved proteins were transferred in activated 0.45μm or 0.20μm pore-size PVDF 
membranes (in ethanol-water) through semi-dry or wet transfer. Membranes were 
subsequently blocked for 30-45 minutes at room temperature with 1% BSA in TBS-Tween 
solution. Incubation with the primary antibody was performed overnight at 4OC with mild 
shaking. After three consequent washes with 1xTBS-Tween for 10 minutes, membranes were 
incubated for 30-60 minutes with mouse or rabbit secondary antibody prepared in 1% BSA in 
TBS-Tween solution. A last round of washing step was followed by visualization of the 
peroxidase-coupled secondary antibody with Western Lighting PLUS-ECL Chemiluminescent 
Substrate and the signal was detected with the Fujifilm LAS-4000 documentation system. If 
required, membranes were stripped for 30 minutes at 50OC under mild shaking using stripping 
buffer. All washing steps were also performed under soft agitation.  
 
3.2.10. Flow cytometry 
3.2.10.1. EdU incorporation Click-iT for cell cycle analysis 
Cell cycle distribution of T98G cells was determined mainly through pulse-labelling of the cells 
with EdU (5-ethynyl-2’-deoxyuridine, a thymidine analogue) combined with DNA staining. The 
advantage of this technique is a more precise S phase quantification and is based on the 
copper-catalysed chemical reaction (Click-iT reaction) between the alkyne group of EdU and 
the azide-fluorophore (Alexa647 or Cy5) found in the Click-iT reaction cocktail (Fig. 7).  
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EdU-labelled cells (10µM for the last 10 min of treatment) were washed once with 1ml of 1x 
PBS and harvested with 800μl of pre-warmed Accutase. Suspended cells were washed once 
with 1ml of 1% BSA in PBS (further referred to as 1% BSA solution) and fixed sequentially with 
freshly prepared 4% PFA – 1% BSA (15 minutes of incubation in the dark, at room 
temperature) and ice-cold 100% ethanol. Ethanol addition was performed dropwise and while 
gently vortexing the sample to avoid cell clamps formation. At this stage, samples can be 
stored at -20OC for up to 2 weeks. Removal of the fixative was achieved by centrifugation for 
5 minutes at 300xg and one washing step with 1% BSA solution. Fixed cells were further 
permeabilized with 200μl of 0.5% Triton X-100 in 1% BSA or 100μl of saponin-based solution 
(provided by the Click-iT EdU-AlexaFluor647 Flow Cytometer Assay kit). Following 15 minutes 
of incubation protected from the light, samples were mixed carefully with 500μl of 1% BSA 
and incubated for another 20 minutes under the same conditions. Meanwhile, the click-iT 
reaction cocktail was prepared as shown in table 9. Removal of the permeabilization buffer 
by a centrifugation step for 5 minutes at 400xg is followed by a 30 minutes incubation with 
100μl of the homemade kit or 500μl of the Click-iT EdU-AlexaFluor647 protected from the 
light. Samples were further washed once with 1% BSA, resuspended in DAPI/PBS solution (1μl 
DAPI from 40μg/ml stock in 300μl PBS) and analysed using the LRS Fortessa flow cytometer 
(BD Bioscience) equipped with blue (488nm) and red (633nm) lasers. In some experiments, 
the DAPI was substituted with an equivalent like Hoechst33342 or Propidium Iodide. 
 
Table 11. EdU Click-iT reaction cocktail 
A. Homemade kit  B.  Click-iT EdU-AlexaFluor647 kit 
 1ml 
 
 
x1 
reaction 
Reaction buffer 860μl  Click-iT reaction buffer 438μl 
100mM CuSO4 40μl  CuSO4 10μl 
100μM Picolyl-azide sulfo Cy5 10μl  Alexa Flour 647 azide 2,5μl 
20mg/ml Sodium ascorbate 100μl  Reaction buffer additives 50μl 
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FlowJo software was used for the quantification analysis of all measurements. Gating of the 
total number of cells was done in a FSC-A vs SSC-A dot plot, from which a second dot plot 
DAPI-A vs DAPI-W was created to distinguish singlet nuclei from doublets or aggregates. These 
singlet nuclei are displayed in a third DAPI-A vs APC-A (EdU-Alexa647 or EdU-Picolyl-azide 
sulfo Cy5) dot plot. Further gating of the distinct phases of the cell cycle is shown in figure 6.  
 
Figure 7. Cell cycle analysis using EdU-pulse incorporation. 
A) Copper-catalysed reaction of the EdU-incorporated DNA backbone with the fluorophore-tagged picolyl-azide. 
B) Sequential gating of singlet nuclei and distinct cell cycle phases. 
 
3.2.10.2. Cell cycle analysis with PI staining  
After the corresponding treatment indicated form the specific experiment, cells were 
harvested with 800μl Accutase, washed twice with 1ml and 3ml 1x PBS and resuspended in 
300μl of ice-cold PBS. Samples were fixed with 750μl ice-cold 100% ethanol under gentle 
vortexing. Ethanol fixed samples can be stored up to 2 weeks at -20OC. For cell 
permeabilization, 20-30 minutes incubation on ice with saponin-based or 0.5% Triton X-100 
buffers was performed. Following 5 minutes of centrifugation at 500xg, cell pellet was 
resuspended in 100μl of RNaseA solution with a final concentration of 200μg/ml and 
A) 
B) 
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incubated for another 20 minutes. After a final centrifugation step (5 min at 400xg), cells were 
stained with 300μl of PI/PBS buffer (1.5μg/ml final concentration) and analysed on a FACS 
Canto (BD Bioscience) flow cytometer equipped with 633nm red laser. Gating of the total 
amount of cell and singlets was performed in the same way as described in the previous 
section. Cell cycle distribution of the singlet nuclei is displayed in a histogram of propidium 
iodide-A (Fig. 8A).  
 
Figure 8. Cell cycle distribution and protein activation. 
A) Representative gating of the cell cycle phases in a propidium iodide histogram. B) Measurement of Erk protein 
activation using an Alexa647-tagged antibody.  
 
3.2.10.3. Detection of Erk phosphorylation by flow cytometry 
After EGF stimulation, cells in culture dishes were PBS-washed, harvested, fixed and 
permeabilized as described in section 7.1. Permeabilized cells were blocked for 30 minutes 
with 5% donkey serum / 1% BSA / 1x saponin in PBS and further stained with Alexa647-
conjugated Erk1/2 (pT202/pY204) for 1.5 hours protected from the light. PBS-washed cells 
were resuspended in 300μl PBS and analysed on the LRS Fortessa flow cytometer (BD 
Bioscience) using the red (633nm) lasers. Following the subsequent gating of the cells and 
singlet nuclei, the latter was plotted in an APC-A histogram (Fig. 8B).  
 
3.2.11. Two step cell cycle analysis with NucleoCounter® NC-3000™ 
The NucleoCounter® NC-3000™ system enables a rapid quantification of DNA content by 
image analysis of the samples. After treatment, cells were harvested with pre-warmed 
A) B) 
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Accutase, PBS-washed and thoroughly resuspended in 250μl lysis buffer supplemented with 
10μg/ml DAPI. After 5 minutes incubation at room temperature, cells were mixed with 250μl 
stabilization buffer and loaded into the 2-chamber slide (30μl). The loaded slide is further 
placed on the tray of the instrument where the quantified cellular fluorescence is displayed 
in a DAPI histogram. All solutions used in this protocol: lysis, stabilization and DAPI buffer 
were provided by the company. 
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4. Results 
4.1. Characterisation of the heterodimerizer-induced effect 
4.1.1. Expression of the anchor and effector units within cells  
The heterodimerization system presented in this thesis is composed of two fusion proteins 
(anchor and effector units) and was partially characterized by a former master student, 
Stephanie Bresan. 
The design of the two-unit heterodimerization system incorporated the generation of fusion 
proteins (anchor unit with FKBP/Ras-hvr and effector unit with FRB/NF1) in various 
permutations so as to maximise the chances of effective membrane anchorage of the anchor 
unit and efficient membrane recruitment of the effector unit upon addition of the stimulus. 
As depicted in figure 9, several combinations of the candidate anchor-effector unit pairs were 
tested. 
 
Figure 9. Constructs for the inducible heterodimerization systems. 
The anchor units contains the dimerization domain FKBP fused to K-Ras-hvr and a fluorescent protein mCherry. 
The effector unit is composed from the dimerization binding partner FRB coupled to a RasGAP NF1 and to the 
fluorescent protein, EGFP. 
 
Four anchor units were initially cloned, of which two had a single FKBP domain (designated 
#1 and #2) and two others contained two tandem FKBP domains (designated #3 and #4). By 
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design, all anchor units were tagged with a red fluorescent dye mCherry to visualise 
expression in a live cells. Along similar lines, three effector units, varying in their domain 
orientation, were marked by a green fluorescent dye EGFP (Enhanced Green Fluorescent 
Protein).  
All possible combinations of the candidate anchor and effector units were analysed for their 
expression levels, localisation and membrane recruitment in transfected cells. First, 
transiently transfected HeLa cells revealed a different expression of the fusion proteins where 
the anchor units #2 and #3 had the strongest expression, followed by #1 and #4. Among the 
effector units, #7 was weakly expressed whereas construct #6 showed the strongest signal. 
Construct #5, which lacked the EGFP tag, could not be detected using the GFP antibody (Fig. 
10). 
  
Figure 10. Expression of the anchor and effector units in HeLa cells. 
HeLa cells were transiently transfected with each one of the constructs using PEI as a transfection reagent. The 
next day, cells were lysed and expression of the effector and anchor units was tested using specific antibodies.  
The anchor unit was detected with anti-FKPB and anti-RFP (red fluorescent protein) antibodies. Whereas to 
identify the anchor unit, anti-GFP antibody was used. As a negative control served wild type HeLa. Experiment 
performed by S. Bresan. 
 
In the next step, all detectable constructs were analysed for their localization and membrane 
translocation in response to heterodimerizer-addition, a cell permeable inert rapamycin 
analogue, that results in the coupling of the FKBP and FRB domains. Confocal microscopy 
experiments in cells co-transfected with several combinations of anchor-effector units 
confirmed correct intracellular localization; the anchor units were stably bound to the plasma 
membrane while the effector units were detected by diffuse, green cytoplasmic fluorescence. 
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Upon heterodimerizer addition, the GFP-coupled effector unit was observed to translocate 
towards the mCherry-coupled membrane-bound unit, evident within the first 15 minutes of 
heterodimerizer treatment. Two candidate pairs, #1#7 and #4#7 respectively, showed 
promising results for use as a system in HeLa and MEF, respectively (Fig. 11). The chosen 
anchor-effector pairs were then, stably introduced into HeLa cells by means of lentiviral 
transfection, designated HeLa#1#7 and HeLa#4#7. 
 
Figure 11. Induced translocation of the effector unit (EGFP-FRB-NF1) toward the anchor unit (FKBP/2xFKBP-
mCherry-K-Ras-hvr). 
A) HeLa cells transduced with the anchor and effector unit, #1 and #7 respectively, were incubated with 500nM 
heterodimerizer (iDimerizer) up to 40 minutes. Confocal images were taken prior (0 min) and after 
heterodimerizer addition at the indicated time points. B) Same procedure was performed in MEFs transfected 
with constructs #4 and #7. Experiment performed by S. Bresan. 
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4.1.2. Dose- and time-dependence effects of the heterodimerizer 
Since the response-time of the system varies with the concentration of heterodimerizer 
stimulus used (Inoue, Heo et al. 2005), we sought to determine the conditions best suited for 
our experiments by performing a dose response analysis. Serum-starved HeLa#1#7 cells were 
treated for 1 hour with 5nM, 50nM and 500nM heterodimerizer and then stimulated with 
10ng/ml epidermal growth factor (EGF) to follow Ras activation in time. The results of the Ras 
activity assay thus obtained are presented in figure 12. While EGF induced a rapid activation 
of Ras protein (collectively referring to N-/H-/K-Ras) and its direct downstream effector Erk in 
untreated HeLa#1#7 cells, Ras activity declined (as measured by GTP-bound Ras levels) in all 
the tested heterodimerizer concentrations, with the highest dose strongly inhibiting Erk 
phosphorylation. Based on these results, 500nM heterodimerizer was used in subsequent 
experiments. 
 
Figure 12. . High concentration of the heterodimerizer induced the higher decline in Ras and Erk activity. 
Dose-response westerns of previously starved HeLa#1#7 treated for 1 hour with the indicated dose-range of 
heterodimerizer. Following stimulation with 10ng/ml EGF at the indicated time points, Ras activity was 
determined with a RasGTP pulldown assay. The double band detected from specific anti-Ras antibody 
correspond to K-Ras (upper band) and N-Ras/H-Ras (lower band. Erk phosphorylation levels (pErk) were 
determined using phosphosite-selective antibody. Coomassie RBD: coomassie stain of the Ras binding domain 
used to selectively separate active Ras (RasGTP) from the inactive form. Coomassie staining served as a loading 
control. Experiment performed by S. Bresan. 
 
A second important factor under consideration was the stability of the heterodimerizer in 
culture. We tested serum-starved HeLa#1#7 cells kept in the presence of the heterodimerizer 
for longer periods of up to 16 hours in Ras activity assays after EGF stimulation. All treated 
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cells showed no Ras activity and a strong inhibition of Erk phosphorylation, indicating a long-
term stability of the heterodimerizer (Fig. 13).   
 
Figure 13. Long-term abrogation of Ras and Erk activity upon heterodimerizer treatment. 
Overnight starved HeLa#1#7 were kept in the presence of 500nM heterodimerizer for 1, 4 and 16 hours and 
further re-stimulated with 10ng/ml EGF at the indicated time points. Ras and Erk activity were detected by a Ras 
activity assay and western blot analysis. Coomassie staining served as a loading control. Experiment performed 
by S. Bresan. 
 
4.1.3. The heterodimerization system is Ras-specific 
The heterodimerization system was constructed with the intent of targeting Ras specifically, 
without interfering with Ras signalling cascade at any other level. In order to verify this, we 
monitored upstream and downstream proteins in the Ras pathway in EGF-stimulated, serum-
starved HeLa#1#7 cells in the presence or absence of heterodimerizer. Wild-type HeLa cells 
lacking the dimerization system were included as a biological control (Fig. 14). Note that while 
EGF receptor phosphorylation, and hence its activation, was comparable in wild type HeLa, 
untreated HeLa#1#7 and heterodimerizer-treated HeLa#1#7 despite lower total EGFR levels 
in the latter two, EGF-induced Ras activity and Erk phosphorylation levels were significantly 
reduced in heterodimerizer-treated HeLa#1#7. Since PI3K pathway can be modulated by Ras, 
Akt activity downstream of PI3K was examined. Heterodimerizer-induced Ras inhibition was 
also evident from a decline in Akt phosphorylation. 
The apparent difference in Ras activation between wild type HeLa and HeLa#1#7 may be 
attributed to an overexpression of RasGAP (NF1) and/or generally weaker Ras and EGF 
receptor expression in these cells. 
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Figure 14. The RasOFF system is highly specific to Ras protein. 
Immunoblots analysis to determine Ras activity and its interaction with downstream effectors. Wild type HeLa 
cells served as behaviour control for HeLa cells stably expressing the RasOFF system. Cells were starved 
overnight and then stimulated with 10ng/ml EGF in absence or presence (1 hour) of 500nM heterodimerizer at 
the indicated time points. Representative immunoblots of RasGTP levels, its downstream (Erk, Akt) effectors and 
upstream proteins (EGFR). Activity of two related small GTPases (RalA and Rap1) were also determined. 
Coomassie staining served as a loading control. pAkt: detection of the phosphorylated Akt. pEGFR: detection of 
the phosphorylated EGFR. Experiment performed by S. Bresan.  
 
In addition, the activity of two other small G proteins, Rap1 and RalA was investigated. 
Interestingly, only Rap1 was stimulated by EGF, while RalA showed a steady basal activity. 
Heterodimerizer addition did not alter Rap1 and RalA activities. In case of HeLa#4#7, Ras 
activity was not inhibited upon heterodimerizer treatment, suggesting that the physical 
binding of the anchor and effector unit does not necessary lead to a biological function of the 
system (data not shown).  
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4.2. General strategy to study the role of Ras in G0-G1-S transition  
The inducible heterodimerization system was employed to study importance of Ras in cell 
cycle entry and progression by inhibiting its activity in cells emerging from quiescence. Two 
essential prerequisites dictated our choice of the correct cell model. Firstly, cells must have 
an intact endogenous Ras activity. Secondly, they must be practically amenable to serum-
starvation induced quiescence and serum-supplementation induced cell cycle re-entry. After 
several trials in an exhaustive list of primary cells such as BJ, Wi-38, MRC-5, IMR-90 and 
transformed cell lines like MCF-7, HeLa, HepG2, T98G, we inferred that the latter best fulfilled 
our requirements. 
T98G cells are derived from a human glioblastoma multiforma tumour and can easily be made 
quiescent by serum withdrawal. The proliferation of these cells was reported to be dependent 
on the Ras-MAPK pathway (Szöőr, Ujlaky-Nagy et al. 2016) and no mutations in RAS genes 
have been reported. In spite of possessing certain characteristics of transformed-cells, like 
immortality and anchorage independence (Stein 1979), T98G cells maintained normal 
checkpoint mechanism for G1-arrest in response to serum withdrawal or contact inhibition. 
Moreover, when deprived of serum for 3 – 6 days (DMEM supplemented with 0.15% FCS), 
T98G cells exit the cell cycle to enter a G0 quiescent state (Rytkonen, Hillukkala et al. 2006).  
To determine the shortest and most efficient synchronization method, we starved T98G cells 
for 3, 4, 5 and 6 days. Regardless of the starvation period, over 80% of cells were arrested in 
G0-G1 and the comparison of the cell cycle re-entry after serum stimulation showed no 
difference (Fig. 15). Therefore, in future experiments, T98G cells will be rendered quiescent 
by 72 hours of serum withdrawal. 
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Figure 15. Comparison of the synchronization efficiency upon starvation and tracking of cell cycle re-entry. 
A) T98G cells were induced to enter quiescence upon starvation for 3, 4, 5 and 6 days. T98G cells were kept in 
medium with only 0.15% FCS and then fixed for cell cycle analysis through EdU-pulse (10min) incorporation of 
newly synthesized DNA followed by a copper-dependent Click–iT chemistry based-detection. B) Quantification 
of cell cycle distribution of actively cycling and starved cells. C) Tracking of cell cycle re-entry and progression up 
to 20 hours upon FCS stimulation of quiescent T98G cells. D) Quantifications of G0G1 and S phase after 12 and 
20 hours of release of T98G emerging from quiescence. Values are presented as mean ± SD of three independent 
experiments.  
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4.2.1. Generation of stable cell lines 
The anchor and effector units of the heterodimerization system were simultaneously 
introduced in T98G cells through a lentiviral transfection. After 1 week of puromycin 
selection, a FACS-Sorting of the double positive cells was performed. Sorted T98G #1#7 were 
analysed for the physical presence of the constructs #1 and #7 within the cell through western 
blot analysis. As shown in figure 16A the overall expression of both constructs in our culture 
was stable.  
As a second step, T98G#1#7 cells were used to test the functionality of the RasOFF 
heterodimerization system through a RasGTP pulldown assay. Previously starved T98G#1#7 
cells were incubated with 500nM heterodimerizer for 1 hour and subsequently stimulated 
with EGF for the indicated time points (Fig. 16B). Upon EGF stimulation of the control set, Ras 
is activated and reached a peak within the first 5 minutes. Longer EGF stimulation shows a 
decline of its activity to a basal level. Treatment with the heterodimerizer induced reduction 
of RasGTP levels and a moderate Erk inactivation. Akt activity was unaltered. Under identical 
settings, the activity of the downstream Ras effector, Erk, was monitored by flow cytometry 
in one of the clones. Administration of the heterodimerizer induced a repression on Erk 
phosphorylation levels. Progressive rightward shift of histograms with time compared to the 
EGF-unstimulated sample in the control (Control) series indicate an increase in Erk activity, 
while reduced p-Erk signals (no rightward shift of peaks) in the treated (iDim) series reflect 
Erk is inactive (Fig. 16C).  
During confocal microscopy experiments, we noticed a wide variety of the green fluorescent 
intensity (EGFP expression) emitted by cells, whereas only a small portion showed a bright 
EGFP signal. The opposite was observed for construct #1 FKBP-mCherry-K-Ras-hvr, of which 
T98G #1#7 cells displayed a very homogeneous mCherry (red) signal (Fig. 16D).  
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Figure 16. Transduced T98G #1#7 cells. 
A) Transduced and sorted T98G#1#7 cells were tested for the expression of the effector and anchor unit through 
western blot analysis. Wild type T98G cells served as negative control, while T98G cells transduced only with the 
anchor unit served as single positive control. The presence of the #7 effector unit was detected with anti-FRB 
antibody, whereas the #1 anchor unit with anti-RFP antibody. B) Representative immunoblot (1 of n=2) of 
untreated and treated T98G#1#7 cells with heterodimerizer. Starved cells were incubated for 1 hour with 500nM 
heterodimerizer prior to EGF stimulation (10ng/ml). At the indicated time points samples were processed for 
RasGTP pulldown assay. Coomassie staining served as a loading control. C) Under identical conditions a flow 
cytometry analysis was performed to detect Erk phosphorylation levels. D) Confocal microscopy of T98G #1#7 
cells. Note the heterogeneity of the #7 effector unit between cells, in contrast to the homogeneity of the #1 
anchor unit. 
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4.3 Evaluation of Ras importance in cell cycle re-entry of quiescent cells 
We continued our investigation by testing the cell cycle re-entry of quiescent T98G#1#7 cells. 
After 3 days of starvation with 0.15% FCS, cells were stimulated to enter the cell cycle in the 
absence or presence of the heterodimerizer. FACS analyses for the cell cycle distribution were 
performed after 12 and 16 hours of release (Fig. 17). Our initial results indicated a significant 
decrease or delay in the proportion of cells entering S phase when Ras activity was inhibited 
using the RasOFF system. These data confirm not only the requirement for Ras activity in cells 
emerging from quiescence as shown in the literature, but also the ability of our 
heterodimerization system to effectively attenuate Ras activity and consequently decrease S 
phase entry of serum-stimulated quiescent cells. The reduction of S phase entry can be due 
to the heterogeneity of T98G#1#7 culture observed during confocal microscopy experiments.  
 
 
Figure 17. Determination of the cell cycle progression for T98G #1#7 cells emerging from quiescence. 
A) T98G#1#7 cells were made quiescence after 72 hours of 0.15% FCS. Cell cycle re-entry upon serum stimulation 
was performed in the absence (-) and presence of 500nM heterodimerizer (+). At the indicated time points cell 
cycle distribution was determined through EdU incorporation in flow cytometry. B) Quantifications of S phase 
at the end of the synchronization (Starved), after 12 and 16 hours of release. Values are presented as mean ± 
SD of three independent experiments. Statistical significance was calculated using two-way ANOVA. **p<0.01, 
***p<0.001   
 
In order to ensure expression of the anchor and effector subunits in stoichiometric 
proportions to improve efficiency of the heterodimerization system, we resorted low- and 
high-EGFP cells from parental T98G#1#7 cultures, P4B/L and P6 respectively (Fig. 18), as well 
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as isolated single cell clones from them. Most of the single clone cultures expressed a weak, 
though homogenous EGFP signal (data not shown).  
 
Figure 18. Representative gating strategies. 
T98G#1#7 cells were first gated for mCherry expression and subsequently for similar EGFP intensity (populations 
P4B, P4L and P6). Wild type T98G cells were used as double negative control.   
 
We proceeded by comparing Ras inhibition, upon heterodimerizer treatment, of the twice-
sorted populations and the clones through Ras activity assays. Figure 19 shows a 
representative immunoblot for one of clones (G4) and one of the twice-sorted populations 
(P6). Overnight starved cells were treated with 500nM heterodimerizer for 1 hour and further 
stimulated with 10ng/ml EGF at the indicated time points. The heterodimerizer-induced Ras 
inhibition was observed in both cases, but the clone demonstrated a significantly higher effect 
on Ras. Decline in Erk phosphorylation was also more visible in the clone than the twice-sorted 
cells. Akt activity instead remained largely independent of Ras inhibition in both cultures. 
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Figure 19. Heterodimerizer-mediated effect on Ras-GTP levels and its downstream effectors. 
T89G#1#7 cells deprived of serum, treated or untreated with heterodimerizer for 1 hour were challenged for 
the indicated time frames with 10 ng/ml EGF. Representative immunoblot of Ras pulldown assay (1 of n=2) 
showing RasGTP levels and its downstream effector activities upon heterodimerizer addition of P6 population 
(A) and G4 clone (B). Coomassie staining served as a loading control. 
 
For all the clones and populations, FACS analysis for the cell cycle distribution were also 
performed in cells emerging from quiescence in the absence and presence of the 
heterodimerizer. Twice-sorted populations showed a similar S phase entry like the parental 
T98G#1#7 cells (Fig. 20).  
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Figure 20. Behavioural comparison of twice-sorted cells with the parental T98G#1#7. 
A) Comparison of serum-stimulated cell cycle re-entry of quiescent once-sorted with the double-sorted 
T98G#1#7 in absence (-) or presence (+) of 500nM heterodimerizer. Cells were rendered quiescent after 72 hours 
of serum withdrawal. Cell cycle distribution was achieved through EdU-pulse labelling/DAPI flow cytometry. B) 
Quantifications of S phase for starved cells, 12 and 20 hours of release after serum addition. Measurements 
were performed once for 4B, 4L and P6 populations and in triplicate for the T98G#1#7. 
 
All tested clones (E9, G4 and G10) had a better arrest in G0G1 phase and subsequently a lower 
S phase entry (12h of release) and progression (20h of release) compared to the parental 
T98G#1#7 (Fig. 21).  These results indicated that a more homogenous culture led to a better 
inhibition of Ras activity which in turn induced a higher reduction of S phase entry in serum-
stimulated quiescent cells. For this reason, all further experiments were performed with the 
clones and will be referred as T98G#1#7.  
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Figure 21. Behavioural comparison of monoclonal cultures with the parental T98G#1#7 cells. 
T98G#1#7 cells were made quiescent through 3 days of serum withdrawal and subsequently stimulated to re-
enter cell cycle in the absence (-) or presence (+) of 500nM heterodimerizer. Cell cycle re-entry and progression 
was followed up to 20 hours after serum stimulation. A) Cell cycle profiling was performed using the EdU-pulse 
labelling / DNA staining flow cytometry. B) Quantifications of S phase for starved cells, after 12 (upper graphic) 
and 20 hours of release (lower graphic).  
 
4.4. Validating the specificity of the RasOFF system  
4.4.1. Mutant NF1(R1276P) has no effect on Ras activity 
A system to manipulate dynamic signalling cascades must be validated with appropriate 
controls. As shown earlier, HeLa #1#7 cells behaved just as wild type HeLa, unless treated with 
the heterodimerizer. This demonstrates that the presence of constructs #1 and #7 do not by 
themselves affect Ras activity or its downstream effectors in any detectable way.  
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Additionally, a second HeLa#1#7 cell line harbouring a mutant, inactive effector unit #7 EGFP-
FRB-NF1(R1276P) shown to abrogate its RasGAP activity (Klose, Ahmadian et al. 1998) was 
generated as an independent control for the specificity of the heterodimerizer system. 
Transduced cells were puromycin-selected for 1 week and sorted for red/green double 
positive cells. The sorted cells will be referred to as HeLa#1#7NF1(R1276P). Expression of the 
two units was confirmed by western blot analysis (Fig. 22A). Wild type HeLa cells were used 
as a negative control, whereas HeLa cells expressing only the anchor #1 or effector unit 
#7NF1(R1276P) served as single positive controls. 
 
Figure 22. HeLa#1#7NF1(R1276P) have no alteration in Ras activity upon heterodimerizer administration. 
A) Expression of the anchor #1FKBP-mCherry-K-Ras-hvr and effector unit #7EGFP-FRB-NF1(R1276P) in stably 
transduced HeLa cells. Wild type HeLa cells were used as a double negative control, whereas HeLa stably 
transduced with the anchor or effector unit served as single-positive controls. *mutant #7FRB-EGFP-
NF1(R1276P) B) Representative immunoblot of HeLa#1#7NF1(R1276P) treated or untreated with 
heterodimerizer. Cells were starved overnight and incubated for 1 hour with 500nM heterodimerizer before 
being stimulated with 10ng/ml EGF at the indicated times points. Samples were further prepared for Ras-GTP 
pulldown assay. Coomassie staining served as a loading control. 
 
To characterize these cells, Ras activity was verified in HeLa#1#7NF1(R1276P) upon EGF 
stimulation, which were previously starved and treated with heterodimerizer (Fig. 22B). As 
expected, no alterations in Ras activity or its downstream effector Erk was detected.  
To exclude the possibility that for some unknown reason the induced translocation of the 
mutant effector unit toward the plasma membrane does not occur, confocal microscopy 
experiments were performed with HeLa#1#7NF1(R1276P). As shown in figure 23 the anchor 
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unit #1 is bound to the plasma membrane while the effector unit #7NF1(R1276P) is spread 
throughout the cytoplasm. The addition of the heterodimerizer resulted in the co-localization 
of the effector and anchor unit at the plasma membrane.  
 
Figure 23. Heterodimerizer-induced translocation of the cytoplasmic unit #7NF1(R1276P) towards the 
membrane-bound unit #1FKBP-mCherry-K-Ras-hvr in HeLa cells. 
Stably transduced HeLa#1#7NF1(R1276P) cells were incubated with 500nM heterodimerizer. Confocal 
microscopy images were taken prior and after heterodimerizer addition.  
 
4.4.2. The heterodimerizer alone has no effect on wild type T98G cells 
The heterodimerizer AP21967 used to activate the system is a rapamycin analogue that no 
longer has the ability to interact with the wild type form of FRB, part of the NF1-coupled 
effector unit #7. To verify that the heterodimerizer itself does not have any effect on Ras 
activity, a RasGTP pulldown assay was performed using wild type T98G cells (Fig. 24A). EGF 
stimulation of the control serum-starved T98G cells induced an immediate Ras activation, 
which was not altered by the administration of the heterodimerizer. Erk protein was also 
equally activated in untreated and treated T98G cells.  
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The lack of effect of the heterodimerizer on cell cycle progression was also investigated. Wild 
type T98G cells were first made quiescent and then stimulated with serum to re-enter the cell 
cycle in the absence or presence of the heterodimerizer. Since the heterodimerizer is 
dissolved in 100% ethanol, treatment of wild type T98G cells with the latter served as internal 
control. As expected, no difference was found in S phase (20h of release) between the control 
and the treated cells. To further confirm these results, T98G cells stably transduced only with 
the anchor unit #1 (designated as T98G#1) were made quiescent and re-stimulated to enter 
the cell cycle with and without heterodimerizer. S phase quantifications showed no significant 
difference between the control and treated T98G#1 cells. The results obtained are presented 
in figure 24 B and C. 
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Figure 24. Heterodimerizer administration has no effect on wild type T98G cells emerging from quiescence. 
A) Overnight starved T98G cells were treated or not with 500nM heterodimerizer for 1 hour and further spiked 
with 10ng/ml EGF for the indicated time points. RasGTP pulldown and western blotting was performed to detect 
Ras, Erk and Akt activity. Coomassie staining served as a loading control. B) T98G cells were made quiescent 
after 72 hours of serum withdrawal (0.15% FCS) and released in the cell cycle in the presence or absence of 
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500nM heterodimerizer or Ethanol. Cell cycle profiles were analysed by click chemistry-based fluorescent 
labelling and flow cytometry in combination with DNA content dye. Quantifications of S phase values are 
presented as mean ± SD of three independent experiments. C) T98G#1 cells were induce to quiescence after 72 
hours of serum starvation (0.15% FCS) and further re-stimulated to re-enter the cell cycle with and without 
heterodimerizer (500nM). Quantifications of S phase values are presented as mean ± SD of two independent 
experiments. 
 
4.5. Ras activity in G0/G1 and G1/S transition  
4.5.1. Temporal profiling of Ras activity during G0-G1-S phase transition 
The use of anti-Ras antibodies in cells emerging from quiescence demonstrated a requirement 
for Ras activity in multiple steps during G0-G1-S transition. Dobrowolski et al. identified the 
presence of 2 temporally distinct peaks of Ras activity during G1 phase: one in the beginning 
and one in mid-to-late G1 stage (Dobrowolski, Harter et al. 1994). In the absence of an 
expeditious approach to modulate Ras activity, its frequency and amplitude required during 
G1 phase is still unclear. Given these conditions, we started investigating the activity of Ras 
and its downstream effector kinases Erk and Akt in T98G#1#7 cells emerging from quiescence 
into G1. Cells were induced to acquire quiescence by serum withdrawal and then stimulated 
to re-initiate cell cycle with or without heterodimerizer treatment, either at release or 1h later. 
At the indicated time points, samples were prepared for a Ras-GTP pulldown assay followed 
by western blotting.  
As a very first observation in this cell line, we noticed a lack of a genuine peak for Ras activity 
at mid/late G1 phase, but a rather continuous basal level until the end of time course studied. 
Growth factor stimulation induced an immediate Ras activity that reached its peak within the 
first 10 minutes. Upon heterodimerizer administration, Ras-GTP levels and its major 
downstream effectors (p-Erk) are strongly decreased. Phosphorylation levels of Akt remain 
unaltered, indicating its regulation is independent of Ras activity at this juncture in the cell 
cycle (Fig. 25). 
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Figure 25. Kinetics of Ras activity in quiescent T98G#1#7 cells treated with heterodimerizer at release or 1 
hour later. 
After 72 hours of starvation with 0,15% FCS, T98G#1#7 cells were stimulated to re-enter cell cycle with growth 
media supplemented with 10ng/ml EGF and treated with heterodimerizer at release (0h iDim) or 1 hour later 
(1h iDim). At the indicated time points samples were processed for RasGTP pulldown assay and western blotting. 
Coomassie staining served as a loading control. 
 
Under identical settings, experiments were performed to investigate cell cycle distribution of 
cells emerging from quiescence when Ras activity was turned off. T98G#1#7 deprived of Ras 
function were not able to enter the cell cycle which has been also shown in previous studies. 
Interestingly, blocking Ras after the first activity peak resulted in the same outcome, 
suggesting that Ras activity is necessary beyond that first activity peak for cells to progress 
into S-phase. Our results evidence the obligate requirement of Ras function in cells emerging 
from quiescence not only in early G1 but also later. Gille and Downward demonstrated that 
multiple signalling pathways were involved in mediating Ras-induced G1 phase progression 
of quiescent cells after serum stimulation (Gille and Downward 1999). Along with the MAPK 
pathway, the second main player was the activation of PI3kinase that induced cyclinD1 
transcription and E2F activity through serine/threonine kinase Akt/PKB. To discriminate 
between the two most direct signalling cascades relayed from active Ras during G0 to G1 
transition, quiescent T98G#1#7 cells were released in presence of two different inhibitors, 
U0126 and LY294002. The utility of U0126, a highly selective inhibitor of the MAPK pathway 
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at the level of MEK, was exploited as an alternate means of interfering with this pathway, in 
addition to Ras. LY294002 is a potent PI3K pathway inhibitor that inhibits cell cycle 
progression through the Akt-FOXO-CyclinD1 axis (Muise-Helmericks, Grimes et al. 1998).  
 
Figure 26. Cell cycle distribution of quiescent T98G#1#7 cells stimulated to re-enter the cell cycle in the 
presence of heterodimerizer, MEK or PI3K inhibitor. 
T98G#1#7 cells were induced to exit the cell cycle through 72 hours of serum withdrawal (0.15% FCS). Re-entry 
and progression into the cell cycle were performed in absence or presence of 500nM heterodimerizer or one of 
the inhibitors: 10μM U0126 (MEK inhibitor) and 25μM LY294002 (PI3K inhibitor). A) Global nucleotide 
incorporation and cell cycle profiles were obtained using the EdU-pulse labelling / DAPI flow cytometry. 
Repetitions of the same time points are shown for reasons of clarity (grey). B) Quantification of S phase 
represented as mean ± SD of three independent experiments. Statistical significance was calculated using two-
way ANOVA. ***p<0.001, 0h iDim/U0126/LY294002: treatment at release. 1h iDim: treatment 1 hour after 
release.  
 
As shown in figure 26, PI3K inhibition abrogated cell cycle progression completely as 
expected, whereas MEK inhibition resulted in an effect similar to the heterodimerizer 
treatment, suggesting that MEK-Erk pathway is the likely mediator of Ras signals under these 
circumstances. 
  Results 
 
69 
 
4.5.2. An alternative method to analyse cell cycle progression  
Under an agreement with ChemoMetec GmbH, we had access to NucleoCounter® NC-3000™, 
a multicolour fluorescent cell-analysing instrument that uses an automated image cytometry 
technology to characterize cell properties. The software captures several images for each 
sample pre-stained with DAPI (a nuclear DNA content stain) and presents the results of the 
cell cycle distribution as histograms. Quiescent T98G#1#7 cells were triggered to start 
proliferating upon serum addition in the presence of the heterodimerizer or MEK/PI3K 
inhibitors. After 24 hours, cells were harvested and prepared for analysis with the 
NucleoCounter® NC-3000™. Also in this case, inhibition of Ras activity in cells emerging from 
quiescence lead to an arrest in G0 regardless of the time of the administration of the 
heterodimerizer to the cells. The PI3K inhibitor, LY294002, strongly blocked G1 phase entry 
and progression, while the MEK inhibitor, U0126, induced cell cycle arrest of cells to the same 
extent as the heterodimerizer (Fig. 27).  
 
Figure 27. Fluorocytometric analysis confirms a block in cell cycle progression in cells treated with 
heterodimerizer (iDim). 
T89G#1#7 cells were rendered quiescent after 3 days of serum starvation and released back into the cell cycle 
in the presence or absence of the indicated drugs. The heterodimerizer and inhibitors were administered 
simultaneously with release or 2 hours later, as labelled. Cell cycle profiling was performed by DAPI staining and 
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cytophotometry analysis using the NucleoCounter® NC-3000™ device 24 hours after release. Dotted line is an 
arbitrary gate separating G0/G1 from S-G2-M phases. The percentages on each histogram show the 
quantifications of G0G1 versus S-G2-M phases. UO126: MEK inhibitor. LY294002: PI3K inhibitor. 0h iDim: 
treatment at release. 2h iDim/U0126/LY294002: treatment 2 hours after release. 
 
4.6. At which time point does the G1 phase become independent of Ras signalling? 
The mandatory requirement of Ras during G1 phase of cells emerging from quiescence has 
been proved by many studies, however the duration of this dependency is not yet clear. To 
determine whether Ras activity is continuously required and indispensable to G1 phase 
progression, we continued our investigation by turning off Ras, advancing periodically, 
throughout G1 phase in cells released from quiescence. Previous experiments indicated that 
quiescent T98G#1#7 cells need between 10 and 12 hours after serum stimulation to transit 
through G1 and begin S phase. Therefore, samples were treated with heterodimerizer such 
that Ras was switched off every 1 hour throughout G1 and were followed until 20 hours after 
being released. Figure 28 consolidates cell cycle distribution of the entire series of samples at 
12 and 20 hours of release. 
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Figure 28. Administration of the heterodimerizer throughout G1 phase for T98G#1#7 cells emerging from quiescence. 
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Administration of the heterodimerizer up to 5 hours after serum stimulation, significantly 
reduced G1 to S transition and progression. Inhibition of Ras activity later during G1 phase 
had no effect on S phase entry or progression. As previously shown, T98G#1#7 were 
characterized by only one peak in Ras activity in early G1, which is not enough to drive cells 
through G1 and S phase. These results indicate that cells emerging from quiescence depend 
on mitogenic Ras signals at least until mid G1 phase. 
Cell cycle progression is controlled by a specific and well conserved mechanism composed by 
several cyclin-cyclin dependent kinases (CDKs) complexes specific for every phase of the cell 
cycle. Progression through G1 phase and commitment to S phase is supported by cyclinD-
Ckd4/6 complexes (Bartek and Lukas 2001). Injection of anti-cyclinD1 and anti-Ras antibodies 
in NIH3T3 cells emerging from quiescence blocked entry into S phase at the same time, 
approximately 4 hours earlier (Hitomi and Stacey 1999b), proving the simultaneous 
requirement of Ras and cyclinD1 in G1 to S phase transition. On the other hand, Gille et al. 
showed that Ras signalling induces cyclinD1 expression (Gille and Downward 1999). To 
confirm this possibility in our system, quiescent T98G#1#7 were stimulated with serum to re-
enter the cell cycle under different schedules of turning Ras off: 1) released in total absence 
of Ras function (0h iDim); 2) blocking Ras activity after cells experienced the early Ras 
activation (1h iDim) and 3) blocking Ras in mid-G1 phase when its function is less required (6h 
iDim) (Fig. 29).  
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Figure 29. G1 phase expression of cyclinD1 is dependent on Ras activity in cells emerging from quiescence. 
Representative immunoblot (1 of n=3) of downstream effectors of Ras upon heterodimerizer administration at 
release and 1 or 6 hours later. Quiescent T98G#1#7 cells were stimulated with serum supplemented with 
10ng/ml EGF to re-enter and progress through G1 phase in absence or presence of 500nM heterodimerizer. At 
the indicated time points cells were lysed and prepared for western blotting.  
 
Treatment of T98G#1#7 cells with heterodimerizer declined Erk activity, while the small G 
protein RalA and Akt function remained undisturbed. In the control set, cyclinD1 activity was 
detectable only after 4 hours of release. Switching off Ras before or shortly after serum 
stimulation of quiescent cells induced a significant downregulation in cyclinD1 expression 
levels. Delaying Ras inhibition only modestly decreased cyclinD1 levels; these CyclinD1 levels 
were apparently sufficient to drive cells into S phase. These differences in the expression of 
cyclinD1 are confirmed by the change in phosphorylation levels of retinoblastoma protein 
(pRB2). In quiescent cells, pRB is active (hypophosphorylated state) and bound to E2F 
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transcription factor blocking entry into S phase. pRB inactivation (hyperphosphorylated state) 
by cyclinD1-CDK4/6 complexes results in the release of E2F that in turn promotes expression 
of genes necessary for S phase progression (Giacinti and Giordano 2006). The shift between 
hypo- and hyper- phosphorylation levels of pRB2 is visible in the control and the 6h iDim set 
where cyclinD1 expression is high and cells progress through G1 and enter S phase. The 
opposite was observed in cells lacking Ras activity and as a result of lower cyclinD1 expression.  
 
4.7. Investigating the role of Ras in cycling T98G#1#7 cells 
4.7.1. Asynchronous cycling cells arrest in G0G1 in absence of Ras activity 
Literary evidence claims that in actively proliferating cells, the commitment to proliferate is 
not made during G1, but rather in the preceding G2 phase in a mitogen-induced Ras-
dependent manner (Hitomi and Stacey 1999b). Following this argument, we started treating 
asynchronous cycling T98G#1#7 cells with heterodimerizer and then analyse their distribution 
throughout the cell cycle. Cells were cultured in the presence of the heterodimerizer for 48 
hours and the results are shown in figure 30. The effect of the treatment is already visible at 
24 hours and is enhanced at 48 hours. Switching off Ras protein forced cells to arrest in G0G1 
phase at the expense of S and G2M phase. 
 
Figure 30. Activation of RasOFF system induced time-dependent accumulation in G0G1 phase of actively 
proliferating cells. 
Actively cycling cells were kept in the absence or presence of 500nM heterodimerizer for 48 hours. Cell cycle 
profiling was obtained through EdU-pulse labelling/PI flow cytometry (on the right). Quantifications of the cell 
cycle distribution shown as percentage of total (on the left).  
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4.7.2. Synchronized T98G#1#7 cells  
In order to investigate whether Ras dictates commitment to subsequent proliferation in the 
current G2 phase, two different strategies were tried in parallel. The first one synchronizes 
the cells in G1/S border through thymidine treatment, while in the second strategy cells are 
arrested in G2 phase by a double block with thymidine and RO3306. In both cases T98G#1#9 
were followed until the next S phase and flow cytometry for cell cycle distribution was 
performed. In both cases, T98G#1#7 cells released from the G1/S or G2/M block after removal 
of the inhibitor continued progression in the next step of the cell cycle as one single 
population, simplifying the process of following cell transition between phases.  
In cells released from the G1/S block, Ras was turned off at three different moments: at the 
beginning of the release (0h iDim set), in early-mid S phase (3h iDim set) and mid-late S phase 
(6h iDim set) (Fig. 31). Despite the treatment, cell cycle progression from S to G2M phase and 
G2M to G0G1 phase was independent of Ras activity. Whereas entry in the next S phase was 
significantly reduced and cells accumulated in G0G1 phase.  
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Figure 31. T98G#1#7 cells released from G1/S block are blocked in the next G0G1 phase in absence of Ras 
activity. 
Cells were synchronized at the G1/S border after 24 hours of treatment with 2mM thymidine. Release into the 
cell cycle was performed in absence or presence of 500nM heterodimerizer at release or later. A) Representative 
time course of cells released from G1/S block. Cell cycle distribution was achieved through EdU 
incorporation/DAPI flow cytometry. Time point repetitions are shown for reasons of clarity (grey). B) 
Quantifications of G0G1 and S phase at 20 hours after release. Values are shown as mean ± SD of three 
independent experiments. Statistical significance was calculated using two-way ANOVA. ***p<0.001, 0h iDim: 
heterodimerizer administration at release. 3h iDim or 6h iDim: heterodimerizer administration 3 or 6 hours after 
release.  
 
With the second approach, when cells were synchronized in G2, Ras activity was blocked from 
the beginning of the release or every 2 hours from G2/M to G1/S transition (Fig. 32). Also in 
this case, progression of the cells in the next G1 phase was independent from Ras activity. In 
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contrast, S phase entry was significantly lower when Ras was turned off before mitosis (0h 
iDim set) and up to 4 hours after being released from the block (2h, 4h iDim sets).   
 
Figure 32. Release of T98G#1#7 cells from G2/M block in absence or presence of the heterodimerizer. 
Synchrony at G2/M border was achieved by a double block with thymidine/RO3306. Removal of inhibitors 
induced release of the cells into the cycle. The heterodimerizer (500nM) was administrated at release (0h iDim) 
or 2, 4, 6 and 8 hours after release (2h iDim, 4h iDim, 6h iDim and 8h iDim, respectively). A) Representative 
determination of the cell cycle progression upon release through EdU labelling/DAPI flow cytometry. Time point 
repetitions are shown for reasons of clarity (grey). B) Quantifications of early (8 hours) and early/middle (12 
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hours) S phase. Values are presented as mean ± SD of three independent experiments. Statistical significance 
was calculated using two-way ANOVA. *p<0.05, **p<0.01, ***p<0.001 
 
To further confirm these results, the expression and activity of two cell cycle regulators, 
cyclinD1 and pRB, was investigated for cells released from the G2 block in the absence or 
presence of the heterodimerizer, either at release or 6 hours later. Upon heterodimerizer 
treatment, Erk phosphorylation is downregulated in both treated sets compared to the 
control, while Akt activity remains unchanged. CyclinD1 levels are detectable at the end of 
the synchronization, since cells are blocked in G2 phase by the double synchronization 
method, in line with previous studies (Yang, Hitomi et al. 2006). Turning off Ras before 
T98G#1#7 are released from the G2 block induced a decline in cyclinD1 levels, but did not 
block it completely. Retinoblastoma phosphorylation levels (pRB2) are detectable only 4 
hours after release because at that time cells are in mid G1. The fluctuation between the 
hypo- and hyper- phosphorylated form reflects the changes in cyclinD1 expression (Fig 33). 
Ras–induced downregulation of cyclinD1 leads to accumulation of pRB2 in the 
hypophosphorylated form. 
 
Figure 33. CyclinD1 expression in T98G#1#7 cells released from G2/M block in the presence of the 
heterodimerizer. 
Representative immunoblot (1 of n=3) of Ras downstream effectors. T98G#1#7 were synchronized at G2/M 
border through a double block with thymidine/RO3306 and further released into the cell cycle upon inhibitors 
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removal. Administration of the heterodimerizer (500nM) was done at release (0h iDim) or 6 hours after release 
(6h iDim). At the indicated time points cells were lysed in RIPA buffer and processed for western blotting.  
 
4.8. Investigating the role of Ras during G2 phase in cycling HeLa#1#7 cells 
The correlation between Ras activity and cyclinD1 in G1 was also detected in HeLa#1#7 cells. 
By using a double block of thymidine and nocodazole, HeLa#1#7 were synchronized in mitosis 
and then released into the cell cycle. Ras activity was turned off 3 hours after release, in which 
more than 50% of the cells are entering G1. Untreated HeLa#1#7 cells expressed two distinct 
peaks of Ras activity, one in early G1 (1h after release) and a second time towards the end of 
G1 phase (10 hours after release) (Fig.34). Surprisingly, we observed a band shift of 
phosphorylated Akt from residue Threonine308 in the early phase of release to Serine473 
towards the end of our experimental time points. The addition of the heterodimerizer 
downregulates Ras-GTP levels reflected in the decline in Erk activity. No alteration of Akt 
phosphorylation level is detected. CyclinD1 expression reached a peak toward the end of the 
G1 phase in the control and also showed that there was no difference in the treated cells.   
 
Figure 34. Ras kinetics of HeLa#1#7 cells released from mitotic block. 
HeLa#1#7 cells were synchronised in mitosis through a double block with thymidine/nocodazole and 
subsequently released into the cell cycle in absence or presence of 500nM heterodimerizer. The release medium 
was supplemented with 10ng/ml EGF. At the indicated time points cells were prepared for flow cytometry or 
western blot analysis. A) Tracking the cell cycle progression of mitotic HeLa#1#7 was monitored through 
propidium iodide FACS analysis for DNA content. B) Representative immunoblot (1 of n=3) of heterodimerzer-
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induced effect on Ras activity and its downstream effectors. The heterodimerizer was administrated 3 hours 
after cells were released. Coomassie staining served as a loading control. 
 
Furthermore, it has been reported that cyclinD1 can be regulated by the PI3K/Akt pathway 
through FOXO (Schmidt, Fernandez de Mattos et al. 2002). To evaluate PI3K-dependent 
cyclinD1 expression, in parallel with the heterodimerizer, cells were treated with the PI3K 
inhibitor, LY294002. HeLa#1#7 were subjected to the same experimental conditions as 
previously described. In addition, a highly selective inhibitor of the MAPK pathway at the level 
of MEK, U0126, was exploited as an alternate means of interfering with MAPK pathway, 
downstream of Ras (Fig.35). Upon heterodimerizer treatment, Ras and subsequently Erk 
downregulation did not alter cyclinD1 expression. MEK inhibitor activated the negative 
feedback on Ras activity (Hennig, Markwart et al. 2016), but no alteration on cyclinD1 was 
observed. Surprisingly, under these conditions LY294002 did not block Akt activity and as 
result neither cyclinD1.  
 
Figure 35. CyclinD1 expression is independent of Ras activity at midG1 in cycling Hela#1#7 cells. 
Synchrony in mitosis was achieved through a double block with thymidine/nocodazole. Upon inhibitor removal, 
HeLa#1#7 cells were released into the cell cycle. After 3 hours of release they were treated with 500nM 
heterodimerizer, 10μM U0126 (MEK inhibitor) or 25μM LY294002 (PI3K inhibitor). At the indicated time points 
cells were prepared for Ras pulldown assay and western blotting. The image is a representative immunoblot out 
of three independent experiments. Coomassie staining served as a loading control. 
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5. Discussion 
 
Ras is a small GTP-binding protein that exerts its function when associated with the plasma 
membrane. Ras protein has the ability to continuously cycle between an active GTP-bound 
and inactive GDP-bound state, under the supervision of two groups of regulators, GEFs and 
GAPs, respectively. Being identified as a key regulator of several signalling pathways like 
proliferation, differentiation, survival and morphology has placed Ras in the centre of the 
signalling transduction research for the last 30 years (Malumbres and Barbacid 2003). 
Nowadays, Ras is a well-known proto-oncogene and gain of function mutations are found in 
up to 30% of all human cancers with the highest incidence in pancreatic, colon and lung 
carcinomas (Bos 1989). Even though a lot of effort has been put in understanding Ras 
activation and interactions with up- and downstream proteins, the temporal dimension of Ras 
signalling is still not fully comprehended.  
Ras has been qualified as one of the key players in the regulatory cell cycle machinery since it 
controls the re-entry of quiescent cells into the cell cycle and decides the cell's fate during G2 
phase. Due to the lack of appropriate techniques, it is not yet completely clear at which 
precise point of the cell cycle Ras function is required or not.  
Through this PhD thesis we will introduce a new experimental technique able to directly and 
accurately target Ras protein. It is based on the rapamycin-induced heterodimerization 
system and can manipulate Ras activity within minutes by switching it off. The 
heterodimerization system was used to interfere with Ras function at several moments during 
the cell cycle progression with the intention to better understand its effect during cell 
proliferation. 
 
5.1 Characterization of the inducible heterodimerization system  
5.1.1 Rapid, induced translocation of the cytosolic effector of the RasOFF system 
The RasOFF heterodimerization system comprises one FKBP-coupled membrane associated 
unit (anchor unit) and one FRB-coupled cytoplasmic unit (effector unit). The anchorage of the 
  Discussion 
 
82 
 
FKBP-coupled unit to the plasma membrane is accomplished by the K-Ras hvr CAAX sequence 
(Parker and Mattos 2015). The FRB-coupled unit was associated to the RasGAP, NF1. The 
inducible translocation of the latter toward the membrane-associated FKBP-coupled unit 
occurred in a short period of time and was visible after only 15 minutes. The speed of the 
translocation is directly dependent on the potential of the chemical dimerizer to immediately 
diffuse through the plasma membrane (Putyrski and Schultz 2012) and probably on the size 
of the protein coupled to the effector unit. The fast translocation and coupling of the two 
units emphasizes the greatest advantage of this system over others that exert their function 
in the range of hours to days. Majority of the contemporary experimental methods to 
manipulate Ras aim to alter the number of the proteins. They are transfection-based 
techniques that make use of plasmid DNA or interference RNA to either upregulate or repress 
Ras expression. The time required for the newly introduced RNA or DNA to be expressed 
within the cell is in the range of a few hours to days after transfection of the target cells. Apart 
from the time-consuming aspect of this method, the effect is often incomplete, non-specific, 
off-target and results are not always equally reproducible (Sledz and Williams 2005). These 
problems are encountered in every experiment performed. Another technique used to target 
Ras is the microinjection of neutralizing anti-Ras antibodies in single cells. The microinjection 
can be performed within 10 minutes in many types of cells, including adherent primary and 
dividing cell lines or suspension cultures, previously seeded on a coverslip. However, the 
disadvantage of this technique is the time required (between 2 hours and 1-2 days) for the 
preparatory and preliminary examinations before the microinjection. Many aspects must be 
taken into account during microinjection. Most of them are cell type specific and include the 
volume of the injected substance and the following incubation time to avoid the diluting 
effect, the injection pressure used during the procedure, number of microinjected cells and 
the survival rate after microinjection (Zhang 2007). In contrast, our heterodimerization 
system exerts its function within 15 minutes and the results are easily reproducible. 
 
5.1.2. Acute inhibition of Ras activity  
The physical translocation of the effector unit leads to the recruitment of the RasGAP, NF1, 
close to the plasma membrane where endogenous Ras in localized. The end result of this 
proximity showed an inactivation of Ras protein probably by accelerating the GTPase 
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hydrolysis. Decline in Ras activity was immediately reflected in its direct downstream effector, 
Erk. Interestingly, growth factor stimulation induced a documented transient Ras activation 
(Waters, Holt et al. 1995, Hennig, Markwart et al. 2016), while Erk activity was maintained for 
a longer period of time indicating a distinct inactivation mechanism. PI3K-Akt axis is activated 
upon EGF-stimulation of Ras and the transient EGF-induced Akt activation (Kumar, Afeyan et 
al. 2007) was downregulated together with Ras. This mechanism was not repeated in T98G 
cells, suggesting a cell type dependency.  
Wild type HeLa cells were used as a control for the behaviour of HeLa#1#7 in the absence of 
the heterodimerizer. EGF and FCS stimulation of both cell lines presented a similar pattern of 
Ras activation and its effectors. In case of insulin-stimulation alone, a potent activator of PI3K 
pathway, Akt phosphorylation levels were higher. Under these circumstances, 
downregulation of Ras had no effect on Akt activity (data not shown).   
HeLa#1#7 cells displayed a marginally lower Ras activity in general, compared to the wild type, 
parental HeLa cells, which might be due to the overexpression of the RasGAP–NF1, in the 
cytosol favouring higher basal rates of GTP hydrolysis. Another plausible explanation is the 
reduced EGFR and total Ras expression in HeLa#1#7 cells. Despite the differences in the 
amplitude of Ras activity, both wild type HeLa and HeLa#1#7 maintained equally proficient 
signalling downstream of Ras. Intriguingly, the overall expression of EGF receptors in 
HeLa#1#7 although lower than in wild type HeLa, receptor activation upon EGF stimulation 
was virtually unaltered in untreated and heterodimerizer-treated cells. Moreover, 
administration of the heterodimerizer did not alter the activity of two related small G proteins 
RalA and Rap1. Despite the shared characteristics of switch I and II regions among small G 
proteins (Caron 2003), the inhibitory effect of neurofibromin (NF1) did not affect RalA and 
Rap1 under these conditions. Simultaneously, the investigations on RalA activity, as the third 
downstream effector of Ras, demonstrated that Ras had no control on its function. Altogether 
our results strongly indicate that downregulation of Ras function upon heterodimerizer 
administration, is an effect of the FRB-mediated translocation of NF1 to the proximity of 
endogenous Ras. The results also prove that the RasOFF system exerts its function in a rather 
specific manner by inhibiting only Ras protein.  
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5.1.3. Dimerization of functional components alone constitute the RasOFF system 
We have demonstrated that the RasOFF system is effective only when both fusion proteins 
and the heterodimerizer are available and fully functional. Our observations showed that the 
missense mutation R1276P in the NF1 protein completely abolished the inhibitory effect of 
the system on Ras protein, even though physical recruitment of the effector unit to the 
plasma membrane was not affected. Mutation of the arginine residue at 1276 into proline, as 
described in the literature, can completely disrupt the GAP activity of the arginine finger of 
NF1, without influencing NF1’s secondary or tertiary structure and especially its ability to bind 
Ras GAP domain (Klose, Ahmadian et al. 1998). Several studies reported that neurofibromin 
inactivation, either through physiological proteosomal degradation or loss of function 
mutations, induced a higher amplitude and a longer duration of Ras activity in response to 
growth factors (Tan, Zhao et al. 2011, Hollstein and Cichowski 2013, Ratner and Miller 2015). 
In addition, in our experiments the use of mutant NF1 fusion protein led to a prolonged Ras 
activity, probably due to competition between endogenous and transduced NF1 molecules 
for the same Ras proteins.   
The chemical inducer used to induce heterodimerization of the FKBP–FRB fusion proteins is a 
rapamycin analogue developed from Adria technologies and lacks the ability to interact with 
wild type FRB (Inoue, Heo et al. 2005). In addition, the FRB domain itself has a T2098L 
mutation that improves the affinity for inert analogues of rapamycin, but also impairs protein 
stability. Nonetheless, heterodimerizer-induced FBKP binding stabilizes the mutant FRB 
(Stankunas, Bayle et al. 2007). This feature of high affinity of the inert rapalog for mutant FRB, 
explains our results in wild type T98G and T98G#1 cells, where cell cycle progression and Ras 
activity were unperturbed in the presence of heterodimerizer, thereby suggesting a lack of 
interaction between the rapamycin analogue and wild type FRB. 
 
5.2 Temporal dynamics of Ras activity during cell cycle progression 
Seminal investigations on cellular proliferative fate decisions, to either continue dividing or 
embrace quiescence, spotted G1 phase as a pivotal point (Zetterberg, Larsson et al. 1995). 
Later studies in actively proliferating cells shed light on the G2 phase and mitogen-dependent 
commitment to either commit or refrain from the next cell cycle (Spencer, Cappell et al. 2013). 
In sum, these studies suggest that transition from quiescence (G0) to G1 phase is controlled 
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by the restriction point in G1, while for continuously cycling cells the commitment to 
complete another cycle is taken in G2 (Matson and Cook 2017). Regardless of the timing of 
the proliferation decision, mitogen-induced Ras activity is of central relevance (Mulcahy, 
Smith et al. 1985).  
 
5.2.1. Advantages and disadvantages of the synchronization techniques  
Throughout this project, we employed various cell cycle synchronisation techniques: 1. serum 
deprivation for 72 hours to obtain quiescent cells and 2. treatment with pharmacological 
agents alone or in combination such as thymidine, double block with thymidine - RO3306 and 
double block with thymidine - nocodazole, to arrest cells in G1/S border, G2 phase or mitosis, 
respectively. These pharmacological agents arrest cell cycle by specific mechanisms. 
Thymidine synchronises cells in G1/S border by inhibiting the activity of ribonucleotide 
reductase required for DNA synthesis (Reichard and Ehrenberg 1983). Nocodazole is a potent 
spindle poison and inhibits microtubule polymerization to arrest cells in mitosis (Merrill 1998). 
RO3306 induces G2 phase synchrony by binding to Cdk1 and interfering with the Cdk1-cyclinB 
complex formation required for G2-M transition (Vassilev, Tovar et al. 2006). The use of 
synchronising agents offered an important advantage especially in the investigation of cell-
cycle phase-associated regulatory mechanisms. However, there is evidence suggesting some 
degree of undesirable or side effects caused by these drugs like alterations in the control of 
cell cycle progression, metabolic perturbations and toxicity (Davis, Ho et al. 2001). The extent 
of these possible side effects varies according to the type of drug, the concentration used, the 
type of cell and the length of exposure to the specific drug. To minimize such negative 
consequences of the synchronization methods, preliminary experiments were performed. 
Another limitation of using pharmacological synchronisation methods is that cells maintain 
synchrony only for one cycle after removing the drug. An alternative technique to study cell 
cycle dependent events was time-lapse experiments combined with microinjection of 
neutralizing antibodies and quantitative fluorescent microscopy (Hitomi and Stacey 2001). 
The major disadvantage of this method was the limited number of cells used, since the 
technique is based in following the behaviour of individual cells. Under these conditions, the 
synchronization methods are still widely used to investigate cell cycle dependent 
mechanisms. 
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5.2.2. Ras is indispensable for cell cycle re-entry and progression of quiescent cells 
Previous studies demonstrated Ras importance in G0 to G1 transition through the use of anti-
Ras antibodies or temperature-sensitive mutant Ras (Durkin and Whitfield 1986, Mulcahy, 
Smith et al. 1985). They further showed that introduction of hyperactivated Ras induced S 
phase entry in quiescent fibroblasts, whereas abrogation of endogenous Ras function in 
normally growing cells led to cell cycle arrest. Our ability to reproduce this established 
concept credits and confirms the functionality, efficiency and stability of the RasOFF 
heterodimerization system in a large population of cells for a relatively long duration (at least 
48 hours).  
We were able to demonstrate that the need for Ras activity did not stop with entry of 
quiescent cells in G1 phase, but was found to be prolonged until late G1. Earlier studies 
indicated multiple activations of Ras during G1 phase, all required for transition of serum 
stimulated quiescent cells in S phase (Dobrowolski, Harter et al. 1994, Takuwa and Takuwa 
1997, Gille and Downward 1999). It was reported that Ras was active throughout G1 and 
reached the highest amplitude twice: in early and mid G1. However, in our case kinetic 
analysis of Ras protein during G0-G1 to S transition depicted a different activation profile for 
T98G#1#7 cells. Upon serum stimulation, these cells expressed one single peak of Ras activity 
in early G1 (within the first 10 minutes of mitogen stimulation). The remaining period of G1 
phase was characterized by a basal and constant Ras activity. This observation suggests a cell-
type dependent activation profile of Ras protein. Despite many investigations described in 
the literature, the possibility and precise schedule of disengagement of Ras signalling with G1 
phase progression is not yet clear; and mistimed Ras activity is at the heart of tumorigenesis. 
In order to fill this knowledge gap, we followed cell cycle progression of mitogen-stimulated 
quiescent cells when Ras was periodically switched off throughout the G1 phase (every 1 hour 
starting from serum stimulation). We found that Ras protein, apart from regulating G1 entry, 
extends its control up to 5 hours after serum addition, but afterwards its signal was not 
required anymore. The commitment for cell cycle progression at 5 hours after stimulation 
suggested the presence of a possible mitogen-restriction point, a model of cell cycle control 
initially proposed by Pardee (Pardee 1974).  
 
  Discussion 
 
87 
 
5.2.3. CyclinD1 expression is under the control of Ras in cells emerging from quiescence 
Mitogen-stimulated quiescent cells’ re-entry into the cell cycle is initiated by the assembly of 
cyclinD1-CDK4/6 complexes. The key player in transmitting mitogenic signals is Ras protein. 
Ras-induced cyclinD1-CDK4/6 complexes start inactivating pRB by inhibitory phosphorylation 
that in turn releases E2F transcription factor. Once active, E2F promotes transcription of 
genes responsible for cell cycle progression and S phase entry, amongst which is cyclinE. In 
parallel, increasing levels of cyclinD1 complexes lead to the sequestration of p21CIP1 and 
p27Kip1 which are stably bound to cyclinE-CDK2 complex. The latter is now active and can 
complete the inactivation of pRB that induces E2F-mediated S phase genes transcription 
(Filmus, Robles et al. 1994, Sherr 2000). In line with this regulatory mechanism of S phase 
entry, heterodimerizer-induced Ras inhibition in T98G#1#7 quiescent cells was associated 
with a downregulation of cyclinD1 expression and no hyperphosphorylation of pRB, partially 
explaining the block in cell cycle entry. The opposite was observed when interfering with Ras 
activity 6 hours after serum stimulation. Cells commitment to proliferate was accomplished 
regardless of the lack of mitogenic signals during the last hours of G1 phase.  
Several reports demonstrated the potential of exogenously expressed, hyperactive Ras in 
increasing cyclinD1 production in quiescent cells lacking growth factors stimuli, thus 
highlighting the critical role of Raf/MEK pathway as major downstream effector of Ras 
(Filmus, Robles et al. 1994, Liu, Chao et al. 1995, Winston, Coats et al. 1996). Moreover, 
translation of cyclinD1 was found to be regulated, at least in part, by the PI3K/Akt pathway 
which in turn can be activated by Ras upon serum or growth factor stimulation (Franke, Yang 
et al. 1995, Rodriguez-Viciana, Warne et al. 1994). The exact mechanism of the crosstalk 
between these two pathways is not completely clear. However, it has been shown that 
NIH3T3 cell treated with a potent PI3K inhibitor (LY294002) caused a much stronger decrease 
in cyclinD1 expression compared to a MEK inhibitor (PD98059) (Gille and Downward 1999). 
The stronger effect of the PI3K inhibitor in this case is a result of inhibiting many downstream 
signalling pathways including serine/threonine kinase Akt/PKB, RacGTPase (part of Rho 
family) and mTOR pathway (Marshall 1996, White, Nicolette et al. 1995, Rodriguez-Viciana, 
Warne et al. 1997). In fact, Akt/PKB has been reported to induce cyclinD1 expression at mRNA 
level (Muise-Helmericks, Grimes et al. 1998) as well as it stabilizes the protein through GSK-
3β (glycogen synthase kinase-3β) (Diehl, Cheng et al. 1998). GSK-3β-mediated 
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phosphorylation of cyclinD1 triggers its export from the nucleus to the cytoplasm during G1/S 
transition. Moreover, Ras mutants lacking the ability to interact with PI3K could not stabilize 
cyclinD1; while Rac GTPase was found to induce cyclinD1 expression (Westwick, Lambert et 
al. 1997). Overexpression of RacGTP was able to activate cyclinD1 promoter and transcription 
probably through NF-kB (Gille and Downward 1999, Joyce, Bouzahzah et al. 1999, Page, Li et 
al. 1999). Additionally, PI3K and Akt/PBK pathway were identified as strong activators of E2F 
transcription factor, even more so than Ras. These findings gave way to new ideas on how 
PI3k and Akt/PKB regulates E2F, for example the CDK inhibitor p27Kip1 (Gille and Downward 
1999). The involvement of many pathways is important in normal cell proliferation because it 
ensures at several levels the optimal conditions from the extra- and intracellular environment 
before the cell commits to division. In our case, the RasOFF heterodimerization system 
downregulated only Erk protein, while Akt activation remained the same. The persistent Akt 
activation, however, could not induce cyclinD1 expression in lack of Ras activity. These results 
gave the first hint that MAPK pathway mediates signals relayed by Ras for G0/G1/S transition, 
at least in T98G cells. To test if this hypothesis is correct, cell cycle analysis was performed 
using the MAPK/Erk and PI3K inhibitors, U0126 and LY294002 respectively, in parallel with 
the RasOFF system. The obtained results showed a dramatic block of cell cycle re-entry and 
progression from LY294002 administration prior to and few hours after serum stimulation. In 
contrast, the U0126 inhibitor had a milder effect, very similar to that of the 
heterodimerization system. Taken together, these results strongly indicate that Ras GTPase 
exerts its regulatory function on the cell cycle control machinery, at least in modulating 
cyclinD1 expression, through the MAPK/Erk pathway.  
Many studies proved the influence of the Ras downstream effector Erk on several levels in 
regulating growth and cell cycle progression. The first demonstration that Ras-activated Erk 
pathway was sufficient to stimulate cyclinD1 expression was reported in the mid ‘90s 
(Albanese, Jonhson et al. 1995, Lavoie, L'Allemain et al. 1996). Other studies reported that 
cyclinD1 expression during G1 phase required continues Erk signalling (Weber, Raben et al. 
1997b, Balmanno and Cook 1999, Roovers, Davey et al. 1999). Even though the exact 
mechanism of Erk-cyclinD1 interaction is not fully understood, there is strong evidence that 
members of the AP-1 proteins, including Fos and Jun, sense Erk activity through the functional 
docking site (DEF domains) on their C terminus and are phosphorylated by it. Once active, AP-
1 proteins can induce cyclinD1 expression (Murphy, MacKeigan et al. 2004). Apart from 
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directly targeting cyclinD1 expression, Erk signalling can modulate G1 to S transition by 
interfering with the nucleo-cytoplasmic transport of cyclinD1 mRNA. The eukaryotic 
translation initiation factor E4 (eIF4E), responsible for mRNA transport (Topisirovic, Capili et 
al. 2002,  Rousseau, Kaspar et al. 1996, Lai and Borden 2000), is phosphorylated and 
subsequently activated by Mnk1/Mnk2 (downstream effector of Erk) at position Ser209. 
Mutations of Ser209 or inhibition of Mnk1/Mnk2 resulted in downregulation of cyclinD1 
(Topisirovic, Ruiz-Gutierrez et al. 2004). Further confirmation of the Erk-eIF4E-cyclinD1 mRNA 
axis, came from the lack of effect of the overexpressed eIF4E on cyclinD1 mRNA distribution 
(Rosenwald, Kaspar et al. 1995, Rousseau, Kaspar et al. 1996).  
Another step of the G1 to S transition dependent on Erk activity is cyclinD1-CDK4/6 
stabilization. This effect is mediated by the CDK inhibitor p21, which accumulates in early G1 
phase upon transient activation of Erk protein (Bottazzi, Zhu et al. 1999,  LaBaer, Garrett et 
al. 1997, Cheng, Olivier et al. 1999). In parallel, p27 is believed to be downregulated by 
Ras/Erk pathway, but the mechanism is not yet clear due to contradictory reports. In this 
regard, there are some reports indicating that downregulation of p27 by Erk is achieved 
through CDK2 and Skp2 proteins (Delmas, Manenti et al. 2001, Mirza, Gysin et al. 2004). A 
more recent finding is the direct interaction of Ras-activated Erk with the TSC (tuberous 
sclerosis complex) complex, part of the mTOR (mammalian target of rapamycin) signalling. It 
was shown that EGF or active Ras mutant can promote mTORC1 activity and tumorigenesis 
by inhibiting the GAP function of TSC. The latter is phosphorylated directly by Erk-RSK (Zoncu, 
Efeyan et al. 2011, Roux, Ballif et al. 2004). Although mTORC1 is activated mainly by PI3K/Akt 
pathway, the TSC2 (GAP TSC) has different phosphorylation sites for each signalling cascade. 
Additionally, Erk/RSK can induce RAPTOR (regulatory-associated protein of mTOR) 
phosphorylation that in turn will lead to 4E-BP activation (Pearce, Komander et al. 2010,  
Carriere, Romeo et al. 2011, Tang, Nunez et al. 1999). Carracedo et al. identified a negative 
feedback loop starting from S6K towards Akt and Erk activity (Carracedo, Ma et al. 2008a). 
Posed with several possible crosstalks between signalling pathways to modulate cell cycle 
progression, further investigation will be required to discriminate and identify those under 
the rigorous control of Ras activity. 
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5.2.4. Switching off Ras induces G0-G1 phase arrest in cycling cells 
The indication that actively proliferating cells commit to cell cycle progression or exit to 
quiescence most probably in G2 rather than G1 was first described by Hitomi and Stacey in 
1999 (Hitomi and Stacey 1999b). Through anti-Ras antibody microinjection in the preceding 
G2 phase and mitogen withdrawal as soon as mitosis is over, they demonstrated that lack of 
mitogen–induced Ras activity was responsible for a reduced progression into S phase of 
NIH3T3 cells. These observations were the starting point for several studies whose focus was 
exploiting G2 phase and the relevance of mitogen-induced Ras signalling. Time-lapse 
fluorescent microscopy investigations identified two subpopulations with clearly distinct 
Cdk2 activity in cells entering G1 after mitosis. Cells with low G1 cellular activity (low Cdk2 
activity) were highly sensitive to mitogen withdrawal after exiting mitosis and left the cell 
cycle until growth factor availability was back to normal levels. On the other hand, cells 
possessing high G1 kinase activity were irreversibly committed to commence and culminate 
the cell cycle. Interestingly, sister cells had equal molecular activity at the end of mitosis, but 
quickly changed as cells entered G1 phase (Matson and Cook 2017). In addition, G2 Ras-
induced cyclinD1 expression was stably maintained until the next S phase. Anti-Ras antibody 
injection as well as introduction of oncogenic Ras in G1 phase failed to alter cyclinD1 
expression suggesting a Ras-dependence of cyclinD1 only in G2 phase for actively proliferating 
cells (Hitomi and Stacey 1999b, Sa, Hitomi et al. 2002).  
Our investigations in asynchronous cycling cells indicated that interfering with Ras signalling 
did induce cell cycle arrest in G1 phase and presumably exit to quiescence. We observed an 
accumulation in G0G1 of T98G#1#7 cells, at the expense of S phase, within the first 24 hours 
of heterodimerizer-induced Ras inhibition and after 48 hours the percentage of cells in G0G1 
phase increased by more than 20%. The time points measured correlate with the first and the 
second cell cycle completed after heterodimerizer addition, since the calculated doubling 
time for this cell line is around 28 hours (ATCC 2012). The progressive increase of cells blocked 
in G0G1 phase supports the idea that the response of cells upon activation of the RasOFF 
system is dependent on the stage in which the cell cycle is. Accordingly, the longer they were 
kept in the absence of Ras activity, the greater the number of cells blocked in G0G1.  
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5.2.4.1 Ras function is required in G2 and/or early G1 phase  
In order to understand when Ras was relevant during cell cycle progression, we abolished Ras 
protein in synchronized cells in S, G2 or in the following G1 phase. Cell cycle analysis through 
flow cytometry of T98G#1#7 cells released from G1/S or G2/M arrest, in absence of Ras 
activity indicated a lower entry in the next S phase if Ras is blocked in S, G2 and in early- or 
mid-G1 phase. However, when measuring the percentage of cells in middle S phase (especially 
after the release from G2/M block) the difference between the control and treated cells had 
decrease. A possible explanation of these results might be that inhibition of Ras activity in the 
preceding G2 phase and/or until the middle of the following G1 phase can prolong 
progression of cells through G1 and consequently delay S phase entry.  Western blot analysis 
of cells released from the G2/M arrest in absence of Ras activity demonstrated a 
downregulation of cyclinD1 expression. As expected, no difference was seen if Ras inhibition 
occurred in mid/late G1 phase. Further investigations are required in order to identify if Ras 
is necessary only in the preceding G2 phase as it is supported by previous studies (Hitomi and 
Stacey 1999a, Hitomi and Stacey 1999b, Sa, Hitomi et al. 2002) or perhaps in early G1 as well.  
Looking at the activation of the two major downstream effectors of Ras, only Erk was 
downregulated reflecting Ras activity and placing it as the mediator of Ras signalling to the 
regulatory cell cycle machinery. However, the implication of Ras/Erk pathway in modulating 
G2/M progression has been continuously questioned due to inconsistent reports, especially 
regarding Erk activity. On one hand, several groups demonstrated an active Erk that if 
inhibited, delayed G2/M transition and cell cycle progression (Liu, Yan et al. 2004, Wright, 
Munar et al. 1999). On the other hand, it was demonstrated that MEK activity was more 
important than Erk (Harding, Giles et al. 2003). 
The common feature observed during the investigations in actively cycling cells and those 
emerging from quiescence was Ras-independent Akt activity. Even though PI3K/Akt pathway 
is considered the second best characterized downstream effectors of Ras, exceptions exist. 
The cell line used in our study for cell cycle progression analysis is the T98G derived from 
glioblastoma multiforme. One of the characteristics of this aggressive cancer is the 
overexpression of epidermal growth factor receptors (EGFR) that increases the possibilities of 
a hyperactivation of Ras/MEK/Erk pathway (Houillier, Lejeune et al. 2006,  Ohgaki, Dessen et 
al. 2004). In addition, other reports demonstrated that to maintain some of the properties of 
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this type of cancer PI3K/Akt pathway is of great importance (Sunayama, Sato et al. 2010a). 
Moreover, it was shown that the existence of a negative feedback that links these two 
signalling cascades where inhibition of either one of them promotes the activation of the 
other (Sunayama, Matsuda et al. 2010). This crosstalk might be a possible explanation of the 
inability of our system to block, at least partly, Akt phosphorylation levels. On the other hand, 
it has been reported that hyperactivation of both Ras/Erk and PI3K/Akt pathways are 
necessary in cancer formation but at a later moment PI3K/Akt can take over and Ras signalling 
is no longer required (Lim and Counter 2005).  
 
5.2.4.2. An alternate cell-model to investigate Ras-dependent cyclinD1 expression 
HeLa#1#7 cells were also used to evaluate Ras function in actively cycling cells. Inhibition of 
Ras activity in mid G1 phase did not impair cyclinD1 expression. Even though the results 
support what we observed in T98G cells, further use of HeLa cells in investigating G1-to-S 
transition is not possible since they have an impaired G1 checkpoint, thus they continue 
proliferating. This is due to the infection with human papillomavirus (HPV) which is 
accompanied by two viral oncogene E6 and E7 (zur Hausen 1999). Expression of E6 and E7 
proteins negatively influences the cell cycle control by inhibiting the normal function of p53 
and pRB, respectively. E6 protein was shown to bind and mediate the degradation of p53 
tumour suppressor protein, while E7 disrupted pRB/E2F complexes by permanently binding 
to pRB (Mantovani and Banks 2001, Munger, Basile et al. 2001).  
Moreover, Akt protein showed a different phosphorylation profile in HeLa cells compared to 
the glioblastoma T98G cells. The shift of the phosphorylation site (from Thr308 to Ser473) in 
cells released from mitosis can be due to sequential phosphorylation process of Akt in order 
to achieve its maximal activation. A second possibility is the detection of three distinct bands 
that correspond to the three Akt isoforms (Akt1, Akt2 and Akt3). The expression and function 
of each isoform within the cells is not yet clear due to controversial findings (Wee and Wang 
2017). We tried to discriminate between the three isoforms using antibodies that specifically 
recognized one of the Akt proteins. Some preliminary data showed Akt1 being 
phosphorylated at Thr308 and Akt2 at Ser473. However, detection of the total Akt indicated 
a higher expression of Akt1 in comparison to the other isoforms (data not shown).  
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Another surprising event that we encountered while working with HeLa cells was the lack of 
Akt inhibition from the PI3K inhibitor, LY294002. The latter is a potent inhibitor of PI3K/Akt 
but exerts its function in a dose- and time- dependent manner. LY294002 is reported to induce 
apoptosis if used in high concentration (30-50μM) and for long periods of time (more than 24 
hours). There is evidence that the response to lower doses of this inhibitor (lower than 30μM) 
is cell-type specific. Jo et al. show a similar Akt activity in HeLa cells, where treatment with 
20M LY294002 for 14 hours did not abolish Akt phosphorylation (Jo, Lo et al. 2011). Other 
studies found that incubation of HCC cells (hepatocellular carcinoma) with 25μM LY294002 
for 48 hours induced a progressive decrease of Akt phosphorylation leading only to G1 cell 
cycle arrest and no induction of apoptosis (Kunter, Erdal et al. 2014). The opposite effect was 
seen upon treatment with 50μM LY294002 for 24 hours in four out of five different human 
primary effusion lymphoma cell lines tested (Uddin, Hussain et al. 2005).  
 
To summarize, our investigation of the functional relevance of Ras in the control of cell cycle 
progression demonstrated its absolute requirement in early G1 phase for both quiescent and 
actively proliferating cells. However, it must be noted that our results in cycling cells cannot 
exclude the possibility that G2 phase Ras activity may take precedence in the commitment to 
the ensuing cycle, as is widely believed in the field. Carefully designed further studies are 
needed to clarify whether Ras activity in G2 is alone sufficient to determine entry into the 
next round of cell cycle or whether Ras function is also essential through the post-mitotic G1-
phase in continuously proliferating cells. Our results complement current-day understanding 
of Ras signalling by clearly demonstrating that cell cycle re-entry of quiescent cells is less 
dependent on isolated peaks of Ras activity in G1 phase, but rather relies heavily on sustained 
Ras signalling until mid-G1, that drives cyclinD1 expression. Investigations into the three 
major effector arms downstream of Ras (Erk, PI3K and RalA), excluded PI3K and RalA as 
mediators of Ras’s cell cycle effects, due to their sustained activity even in absence of Ras 
signalling. It is noteworthy that our data do not support the phenotype documented in Rasless 
MEFs where cyclinD1 was found to be normally expressed, although inactive. Repression of 
Ras activity using the RasOFF system induced downregulation of cyclinD1 and retained the 
pocket protein pRB in its hypophosphorylated form, thus leading to a cell cycle arrest in 
quiescence. Taken together our results portray Erk as the only acutely Ras-responsive 
  Discussion 
 
94 
 
signalling mediator, at least with regard to the control of cell division, particularly responsible 
for cyclinD1 expression in G1 of cycling cells and of cells emerging from quiescence. 
 
Figure 36. Model summarizing Ras activity and involvement in the cell cycle progression. 
A) Cell-type dependent activation profile of Ras protein. Upon serum stimulation, quiescent T98G cells express 
one single peak of Ras activity in early G1, while the remaining period of G1 phase is characterized by a basal 
and constant Ras activity. Dissection of G1 phase demonstrated that G0-G1 to S phase progression is Ras-
dependent up to 5 hours after serum stimulation of quiescent cells. HeLa cells, instead, experienced two genuine 
peaks of Ras activity in early and late G1 phase, respectively. B) Inactivation of Ras protein induced 
downregulation of cyclinD1 probably using Erk as transmitter of its signalling. PI3K pathway, a second cascade 
believed to control cyclinD1, could not induce its expression even though constantly active.  
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6. Conclusions and future perspectives 
 
In this thesis, we present a new experimental technique able to directly and acutely inhibit 
one of the most studied membrane-bound small GTPases – Ras. We have demonstrated that 
the RasOFF heterodimerization system can directly and specifically decrease Ras activity 
without affecting other signalling pathways, including other small GTPases. Furthermore, we 
were able to prove that in the absence of the heterodimerizer, the presence of the two fusion 
proteins did not alter cellular behaviour; and the heterodimerizer itself showed no effect on 
cells lacking fusion proteins.  
At the experimental level, it is important to emphasize the efficacy and applicability of the 
RasOFF system for studying Ras-dependent proliferation of entire cell populations. Most of 
the studies that described the correlation between mitogen-induced Ras activity and cell 
proliferation were performed in single cells, which despite the optimal experimental 
conditions are still not the best representation of what happens under physiological 
conditions. A second advantage of our technique is the simplicity of the system, in that Ras 
inhibition is induced just by the simple addition of an inert, membrane-diffusible 
heterodimerizer to the culture media, as opposed to the harsh antibody microinjection 
method. Last but not least, the RasOFF system can be activated at any desirable time and 
rapidly affects Ras function within minutes.  
By using the RasOFF heterodimerizer system, we investigated the necessity of Ras in the 
overall control of cell cycle. Our data decisively showed that Ras signalling is obligatory for 
quiescent cells to re-enter and progress through G1 phase. We further established that the 
requirement for Ras activity in cells emerging from quiescence extends up to 5 hours after 
mitogen stimulation. On the other hand, actively proliferating cells displayed a stronger Ras 
activity profile during G2 phase followed by a decline as cells progressed through mitosis and 
G1 phase. We were able to demonstrate that S phase entry is controlled by Ras activity via 
regulating cyclinD1 expression in cells emerging from quiescence and actively cycling cells. 
Pharmacological inhibitor studies combined with the RasOFF system indicated that Ras 
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mediates its cell cycle effects via Erk. Strikingly, Akt activity was entirely uncoupled from Ras 
in this context.  
In the near future, our work will be extended to delineate the molecular effectors 
downstream of Ras/Erk, that transmit their signals from the cytosol to the nuclear cell cycle 
control machinery. Further analyses are required to clarify contextual relevance of Ras 
signalling during the G1 phase of actively cycling cells.  
In the long term, the RasOFF system will be employed to investigate importance of Ras in 
inflammation. This will be achieved by introducing the heterodimerization system in immune 
cells by way of creation of a conditional mouse model.
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